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 Due to the tremendous progress of modern medicine, more people are surviving 
cancer. A cancer diagnosis no longer connotes the end of life, but instead, a change in 
life. Recently, middle age and older adults with hematological cancer have become 
eligible for treatment with allogeneic hematopoietic cell transplantation (allo HCT), 
enabling them to survive their underlying cancer diagnosis. While some individuals fully 
recover from allo HCT, up to two thirds of allo HCT recipients develop new-onset 
diabetes. While research has been conducted on the physiological effect diabetes has on 
HCT outcomes, there is a knowledge gap regarding middle age and older adults’ 
psychosocial response to the condition. The objective of this qualitative study was to 
explore the psychosocial experience of developing new-onset diabetes after allo HCT. 
Nineteen participants above 50 years of age were interviewed. Qualitative data generated 
through interviews were analyzed using constructivist grounded theory methods. The 
result was the mid-range theory of dealing with new-onset diabetes as a long-term effect 
of allo HCT. This theory had 4 stages; 1) finding out about diabetes, 2) formulating an 
understanding of diabetes in relation to cancer, 3) formulating a diabetes identity, and 4) 
dealing with diabetes after allo HCT. Three distinct patterns of movement through these 
stages emerged, depending on how participants recovered from their allo HCT.  The first 
pattern occurred in the group of participants with no or minimal after allo HCT 





and the third in those with ongoing complications. Two primary factors were responsible 
for these differences of moving through the stages, and ultimately, whether participants 
adapted to new-onset diabetes: the amount of treatment-related work and the perceptions 
of diabetes. The group with minimal complications was able to understand, identify, and 
integrate diabetes into their lives, while those with ongoing complications experienced 
barriers to socially constructing and identifying with their type of diabetes, and were 
subsequently unable to integrate diabetes into their lives. This mid-range theory provides 
a working framework for the development of clinical and educational interventions 
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 Since its inception in 1968, more than 55,000 people have benefited from 
hematopoietic cell transplantation (HCT) per year world-wide (National Marrow Donor 
Program, 2010). The increased application of HCT to a wider range of disease states and 
patient characteristics has allowed many individuals to survive the underlying disease for 
which they were treated. The fastest growing segment of the HCT population is adults 
above 50 years of age (Pasquini & Wang, 2013). Unfortunately, HCT is not without long-
term effects. Survivors of HCT experience a higher risk for diabetes as both a long-term 
effect (Griffith, Jagasia, & Jagasia, 2010) and late-term effect (Baker et al., 2007). New-
onset diabetes is experienced in up to 30% of HCT recipients (Griffith et al., 2010), with 
rates highest in the older adult allogeneic (allo) HCT recipient population (Baker et al., 
2007).  
 As allo HCT is a relatively new treatment option for middle age and older adults, 
studies exploring older adults’ experience with developing and living with diabetes in the 
context of HCT are absent. Older adult allo HCT recipients with diabetes may have very 
distinct health care needs related to their unique illness experience. Adding this 
information to the HCT knowledge base is vital to planning holistic care for this cohort. 





experience of middle age and older adults when developing new-onset diabetes after 
allogeneic hematopoietic cell transplantation (allo HCT) for the treatment of 
hematological cancer. This was done through unstructured interviews with 19 
participants from a cancer hospital in Southern California. Participants were asked to tell 
about their experience of developing diabetes. Eligible participants included adults above 
50 years of age who developed new-onset diabetes after they received allo HCT for 
treatment of a hematological malignancy at the hospital between 2008-2013. Qualitative 
data generated through these interviews were analyzed using constructivist grounded 
theory methods. In addition, demographic, disease, and clinical data were collected to 
strengthen the description. The outcome of the study was the substantive theory of 
Dealing with Diabetes as a Long-term Effect of Allo HCT. This theory can be used as a 





 The bone marrow is responsible for hematopoiesis, or the production of the cells 
of the blood.  The pluripotent hematopoietic stem cells, under the influence of tissue and 
hormonal factors, differentiate and mature into red blood cells, white blood cells, and 
platelets. This process can be damaged through bone marrow failure, destruction of 
marrow by disease, and chemotherapy and radiation. Disorders of the bone marrow can 
be malignant as observed in leukemia, multiple myeloma, myelodysplasia, lymphoma, or 






 To treat these hematological conditions, hematopoietic stem and progenitor cells 
acquired from healthy individuals can be transplanted into affected individuals. These 
new cells are able to home to the bone marrow, self-renew, and reconstitute the 
hematopoietic and immune systems of the bone marrow. Individuals can harvest their 
own HSCs when disease-free, and have them cryopreserved and then reinfused during a 
period of crisis or disease. HCT from a donor are termed allogeneic transplantations, 
while transplantations from self are autologous transplantations.  
 The transplantation process is similar for both allo HCT and autologous (auto) 
HCT (Ezzone, 2013). The distinct phases of HCT include the conditioning phase, the 
transplantation, the preengraftment phase, and the postengraftment phase. During the 
conditioning phase a preparatory regime is given to the host to 1) eliminate malignant 
cells or residual disease, 2) to immunosuppress the host to allow for graft acceptance, or 
3) to create space in the marrow for the new graft. During the next phase, the 
transplantation phase, the HSCs are infused into the patient via a central venous line. 
Time to engraftment can vary dependent on the nature of the underlying disease, the 
conditioning regimen used, the use of prophylaxis treatments, and any complications that 
occur during this phase, but typically take 2-4 weeks after transplantation. During the 
postengraftment phase, at 1-3 months after transplantation, bone marrow function 
continues to recover. Patients remain immunocompromised and are at risk for significant 
morbidity and mortality. Causes of death in allo and auto HCT are primary disease, 
GvHD (allo HCT only) infection, organ failure, secondary malignancy, and other causes. 





immune system detects the host tissue as foreign and attacks it) for several months to 
years and are therefore placed on an immunosuppressant regime.  
 
The Use of HCT in Middle Age and Older Adults 
 Conditioning regimens use high-dose chemotherapy or radiotherapy treatments to 
ablate the diseased bone marrow. These therapies are associated with significant toxicity 
and mortality (Appelbaum & Thomas, 2009), more so in middle age and older adults and 
the medically infirm than younger, healthy individuals (Sorror & Storb, 2010). As a 
result, individuals above a certain age (50 or 55 years depending on transplant center 
policy) were deemed ineligible for allo HCT (Appelbaum & Thomas, 2009; Sorror & 
Storb, 2010).  This eliminated a potential curative therapy for the majority of individuals 
affected by the hematological malignancies. Table 1.1 shows the average age of onset for 
selected hematological cancers (Appelbaum & Thomas, 2009). 
 In the last two decades, however, chronological age-based restrictions have been 
reconsidered as a necessary exclusion from HCT (Popplewell & Forman, 2002). One 
reason for lifting the exclusion on older adult transplant recipients was research that 
showed less toxic conditioning regimens were found to work almost as well as the more 
toxic regimens. Reduced-intensity conditioning has lower rates of transplant-related 
organ toxicity and decreased nonrelapse mortality, heralding the way for the use of allo 
HCT in previously excluded middle age and older adults (Sorror, 2010). Another reason 
for reconsidering age-based criteria has been an increased understanding of correlates and 
predictors of improved HCT outcomes. As a result, more multidimensional assessments 
are being developed and utilized, such as the comprehensive geriatric assessment 





Comorbidity Index (HCT-CI) (Sorror, 2010). Due to the improved selection process and 
advances in HCT science, adults above 50 years of age comprise the fastest growing 
segment of the HCT population (Pasquini & Wang, 2013; Figure 1.1). This new cohort of 
older adult HCT presents new challenges to the healthcare team in providing timely and 
appropriate post-treatment care. 
 
Diabetes as a Long-term Effect of HCT 
 Despite the improved screening measures and advances in transplantation 
technology, HCT continues to be associated with significant late and long-term effects of 
the toxicity from pretransplantation exposure, transplantation conditioning regimens, 
chronic immunosuppression, and graft-versus-host disease (GvHD). Survivors of HCT 
have been found to have a higher risk for diabetes as both a long-term effect (occurring 
during treatment and persisting after completion of primary treatment) (Griffith et al., 
2010) and late-term effect (occurring months or years after treatment has ended) (Baker 
et al., 2007). Because older age is also associated with higher rates of diabetes after HCT 
(Baker et al., 2007) in conjunction with the rise in middle age and older adults receiving 
and surviving HCT (Pasquini & Wang, 2013), diabetes as a comorbidity of HCT can be 
expected to increase.  Due to the diabetogenic effects of the immunosuppressant regimen 
required in allo HCT, recipients of allo HCT have a higher prevalence of new-onset 
diabetes compared to autologous HCT recipients (Baker et al., 2007). This 
immunosuppression can be sustained for up to a year after transplantation, making the 
post-HCT trajectory different from the auto HCT recipients. Therefore, this research will 






Epidemiology of Diabetes Post HCT 
 Reports on the incidence of new-onset diabetes after HCT vary substantially. 
Griffith and colleagues (2010) conducted a literature review on the incidence of “post-
transplant diabetes mellitus” (PTDM) after HCT. Rates of PTDM ranged from 3.3% in 
those who were 6.2 years (mean) after HCT to 30% in those 2 years from their HCT. This 
wide range may be due, in part, to complexities in the definition and diagnosing of new-
onset diabetes after HCT.  
 Hyperglycemia post HCT can be caused by immunosuppressant medications that 
are used to prevent GvHD. In the majority of individuals, blood glucose levels revert to 
normal after immunosuppressant medications are discontinued. According to the 
American Diabetes Association (American Diabetes Association, 2014a), this is 
classified as “drug- or chemical-induced diabetes, such as in the treatment of HIV/AIDS 
or after organ transplantation” (p. S14).  
 Hyperglycemia can also be the hallmark of overt diabetes due to permanent 
physiological changes in the body’s ability to metabolize glucose that occurred during the 
HCT process. The natural history of diabetes after HCT is unclear (Griffith et al. 2010), 
as is the classification of diabetes acquired after HCT.  In a comparable population of 
solid-organ transplantation recipients, Ghisdal and colleagues (2012) state “It is difficult 
to distinguish late cases of new-onset diabetes after transplantation from genuine cases of 
type 2 diabetes” (p. 181). 
 Currently, identification of new-onset diabetes after solid organ transplantation is 
based on the definition of diabetes provided by the ADA (Wilkinson et al., 2005). The 





marked by high levels of circulating blood glucose. Diabetes is diagnosed by a fasting 
glucose ≥126 mg/dL, random glucose ≥200mg/dL with symptoms (polyuria, polydipsia, 
or unexplained weight loss) confirmed on two occasions (ADA, 2014). Hemoglobin A1C 
assay is not recommended as a diagnostic indicator in diabetes in the transplantation 
setting due to the spurious results seen in conditions of high red-blood-cell turnover 
(Sharif & Baboolal, 2010). 
 Therasse, Wallia, & Molitch (2013) add a caveat to diagnosing diabetes in solid- 
organ transplantation: The diagnosis of new-onset diabetes should not be made in 
presence of infectious process, during acute stress, or while a patient is receiving high 
dose corticosteroids. Furthermore, if the patients was on chronic glucocorticoids, they 
recommend waiting until the patient is on a stable regimen of 10 mg per day or less of 
prednisone, or the equivalent, until the diagnosis of diabetes is made (Therasse et al., 
2013). Figure 1.2 shows the possible presentations of hyperglycemia/diabetes during 
HCT, including diabetes prior to HCT, hyperglycemia as an acute response during HCT 
treatments, and persistent hyperglycemia leading to diabetes after HCT. While this 
definition helps clarify the difference between temporary treatment-related 
hyperglycemia and persistent diabetes related to changes in the body’s ability to 
metabolize glucose, it has not been endorsed by healthcare organizations or widely 
adopted.  Consensus among clinicians and researchers regarding the definitive diagnosis 
of new-onset diabetes after transplantation remains elusive.  
 
The Importance of Timely Glycemic Control 
 Why does it make a difference whether HCT recipients have treatment-related 





HCT recipient may lead to a potential delay in the management of hyperglycemia. 
Uncontrolled hyperglycemia over time is associated with microvascular and 
macrovascular complications. Acute hyperglycemia is associated with symptomatology 
such as polyuria, polydipsia, nocturia, and fatigue that can also negatively impact quality 
of life. Therefore, mitigation of hyperglycemia is a priority of diabetes management, 
beginning early in the disease trajectory and continuing throughout. 
 As Chapter 2 will review in more depth, the communication of a disease diagnosis 
from a health care provider to the patient marks a beginning of a disease course. 
Individuals begin to change their concept of self and subsequently change behaviors. 
How individuals transform and integrate illness is crucial to their ability to control illness 
and to live a meaningful life (Audulv, Asplund, & Norbergh, 2012). A person who 
believes hyperglycemia is a passing symptom may not see glycemic control as important 
and might not bother changing to a healthier lifestyle if the diabetes “will probably go 
away.” This is concerning, as glycemic control through patient self-management is the 
cornerstone of preventing diabetic complications (ADA, 2014).  
 
Statement of the Problem 
 
 It is unknown what middle age and older adults perceive as “developing diabetes” 
and when in the trajectory of conditions that come to be known as “diabetes” they 
experience turning points or psychosocial processes that affect their quality of life or self-
management ability. In the absence of guidelines to support and promote the health of 
patients with new-onset diabetes after HCT, guidelines utilized for diabetes in general are 
applied clinically to this population without proven external validity. Because new-onset 





threatening illness, and has an ambiguous trajectory, it is conceivable that the experience 
of developing diabetes is quite different for this group in comparison to type 1 and 2  
diabetes, and therefore this group may have distinct health care needs.  
 
Purpose and Aims 
 
 The primary objective of this study was to discover the basic psychosocial process 
middle age and older adults undergo when developing diabetes after receiving HCT for 
the treatment of their cancer. Understanding this process and the critical junctures that 
occur during the process will guide health care providers when planning care for this 
patient population. The aim for this study was to develop a substantive theory of the 





 The following research question provided guidance for this study: What is the 
main concern of middle age and older adults when developing diabetes after HCT for the 
treatment of their cancer and how do they resolve this concern? Supporting sub-questions 
of interest included the following: (a) How do middle age and older adults experience 
developing diabetes in the context of cancer and cancer treatment with HCT?  (b) What 
are the transitions, significant events, and critical junctures in the process of developing 




 Recent statistics indicate that there are over 41,000 survivors of allo HCT, with 





(Majhail et al., 2013). These numbers are expected to increase 2.5-fold by 2020 and 5-
fold by 2030 (Majhail et al., 2013). Middle age and older adult HCT survivors can face a 
lifetime of potential health problems such as diabetes. Consequently, research on how to 
manage diabetes in this expanding population is important to guide healthcare initiatives. 
While research has been conducted on the physiological impact diabetes has on HCT 
outcomes (Baker et al., 2007; Olausson, Hammer, & Brady, 2014), there is a knowledge 
gap regarding middle age and older adults’ psychosocial outcomes such as quality of life.  
 An understanding of the patient psychosocial experience together with the 
biophysical information is necessary to inform holistic, patient-centered aspects of allo 
HCT care. With this comprehensive HCT knowledge base, national and workplace policy 
can be crafted to include patients’ goals, priorities, and values. Moreover, new models for 
the management of chronic health conditions (Figure 1.3), such as diabetes and cancer 
survivorship, posit that patient outcomes are improved when patients are informed and 
activated and the healthcare team is prepared and proactive (Bodenheimer, Lorig, 
Holman, & Grumbach, 2002; Wagner, 1998). This study will allow for patients and their 
caregivers to be better informed about diabetes in the HCT context, allowing for 
increased patient engagement. 
 Through the rich descriptions of the older adult HCT recipients’ experience with 
developing and integrating diabetes into their lives, a theory of the basic social process 
was developed. This theory can be used to provide the underpinnings for healthcare 
interactions, interventions, and future research specific to this growing population. Morse 
(2012) noted that while trying to balance technological advances and fulfill patients’ 





dehumanized by the healthcare system. This study adds the patient experience to the 
health care knowledge base, allowing for cancer care that considers the human 
dimensions in illness and caring—cancer care that is humanized (Todres, Galvin, & 




 This chapter presented a brief background of diabetes in the context of HCT. It 
informed the reader about the current state of allo HCT and its association with 
hyperglycemia and diabetes as a long-term effect of cancer treatment. Gaps were 
highlighted in the qualitative research reporting of diabetes after cancer treatments as 
seen through the lens of the person experiencing the condition. The awareness of these 
gaps in knowledge was presented as the impetus for this study. With this context 
communicated, Chapter 2 will review the psychosocial impact new-onset diabetes may 
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Table 1.1 Average age of diagnosis for common  
hematological cancers. 
 
Diagnosis: Common Age of Onset: 
Aplastic Anemia 15-25 years 
Acute Myelogenous Leukemia 65 







Hodgkin Lymphoma 30-50 
Non-Hodgkin lymphoma 65 
Multiple Myeloma 72 








Figure 1.1 Trends in transplantation by age (Pasquini & Wang, 2013).  








Figure 1.2 Possible presentation of hyperglycemia/diabetes  








Figure 1.3 The Chronic Care Model. Reprinted with permission  

















 The specific aim for this study was to develop a substantive theory of the main 
concern and resolution of the concern that middle age and older adults describe when 
developing new-onset diabetes after allo HCT. Chapter 1 reviewed the physiological and 
clinical aspects of new-onset diabetes after HCT. At the end it was noted that there was a 
gap in reports of the patients’ experience with developing diabetes after HCT. There is, 
however, a composite of qualitative healthcare research that describes how individuals 
respond and live with chronic illness(es) in other contexts. This chapter will present some 




 Chronic illness is a condition that last a year or longer, requires ongoing medical 
attention, and/or limits activities of daily living. It is estimated that 1 in 4 Americans has 
multiple (two or more) chronic conditions, and the prevalence and burden of chronic 
illness is disproportionate in middle age and older adults (Institute of Medicine, 2012). 
Since both diabetes and cancer require ongoing efforts by the individual and the 
healthcare team to optimize illness outcomes, they have been delineated as chronic 






conditions they are considered multiple chronic conditions (MCCs). The principal aim of 
interventions for chronic and MCCs is to reduce morbidity and help each affected person 
to “live well.” The Institute of Medicine defines the concept of living well as “the best 
achievable state of health that encompasses all dimensions of physical, mental, and social 
well-being” (Institute of Medicine, 2012, p. 4).  
 By qualitatively studying individuals who have experienced illness and obtained 
the state of “living well” (or of not living well), researchers hope to garner information 
that can help health care providers better understand the patient experience and, 
subsequently, provide patient-centered care for improved outcomes. This is based on the 
theoretical perspective of Symbolic Interactionism by Harold Blumer (1969). Blumer 
(1969) wrote that in an attempt to understand their world, individuals develop subjective 
meanings of experiences—human action is ultimately dependent on these derived 
meanings.  
 When an individual develops an illness, his or her self-identity and previously 
defined meanings of the world change. Understanding the psychosocial process of change 
can provide insight into how the individual ultimately thinks and behaves towards his or 
her illness (Brown, 1995; Charmaz, 1990). Martin & Peterson (2009) agree that studying 
a person’s perception of the illness experience can facilitate the healthcare teams’ 
understanding of the experiences and allow healthcare professionals to “play a more 
proactive role in helping patients negotiate their way through the experience of having a 








Methods for Reviewing Literature 
 
 The search terms chronic illness, qualitative research, chronic illness experience, 
nursing theory, and adults were entered into the following databases: PubMed, CINAHL, 
MEDLINE, Scopus, and Google Scholar. In addition, relevant literature was found by 
reviewing the references lists of resulting articles. The search was of primary, peer-
reviewed sources limited to English language and mostly U.S. studies, due to national 
differences in chronic illness management and conceptualization in other countries.  
Because chronic illness care is rapidly changing, the inclusion dates of 1998-2013 were 
used.  Literature that did not include a majority of older adult participants, such as studies 
conducted on only type 1 diabetes, was not included because of the variation in illness 
experiences between younger versus older people with diabetes. Figure 2.1 shows the 
search strategy. Relevant literature is presented in Table 2.1. Seminal studies conducted 
before the inclusion dates are also summarized.  
Articles in the review included influential qualitative studies and qualitative meta-
analyses of chronic illness experience. Seven articles were included: four were qualitative 
metasyntheses and three were qualitative research studies. The literature synthesis was 
conducted using Process and Focused Coding methods (Saldana, 2013) to identify and 
catalogue commonalities across the seven articles. 
  
Review of Formative Literature Predating This Review 
 
 Much of what we know about patients’ experiences with chronic illness stems 
from research studies conducted by Charmaz (1983, 1990, 1997) and Corbin and Strauss 
(Corbin, 1998; Corbin & Straus, 1988; 1991). These early works provided healthcare 





illness behaviors. Many core concepts were delineated that have been instrumental in 
advancing our understanding of chronic illness.   
 
Illness Identification 
 Using grounded theory methodology, Charmaz (1983) explored the experiences 
of severely disabled chronically ill individuals. Participants in this study spoke of 
suffering losses including the experience they described as a “crumbling away” of their 
former self. These losses were most marked at the onset of a serious illness. Charmaz 
noted that individuals in the study sought to make meaning of their illness and to 
establish a new sense of balance by constructing a new identity. This process of transition 
to the new normal and identity re-establishment is complex with many variables 
including social input from friends, family, society, and the healthcare provider 
(Charmaz, 1983). Participants seldom spoke of heightened consciousness or outcomes of 
a positive nature. The exception to this was individuals whose illness course improved. 
They spoke about their time being sick as a path to knowledge and self-discovery. 
 
The Work of the Person in Chronic Illness 
 In 1988, Corbin and Strauss conducted a grounded theory of 60 couples, of which 
one of the pair was experiencing chronic illness. This study categorized the work needed 
to be done by the person with the chronic illness, illness-related work, everyday life 
work, and biographical work (Corbin and Strauss, 1988). Illness-related work is 
composed of tasks necessary to manage or treat a chronic illness and its sequelae, 
regimen work, crisis prevention and handling, symptom management, and diagnostics. 





shopping, driving, cooking, and cleaning, as well as managing stress, anxiety and 
emotion.  Biographical work refers to the defining and maintaining an identity that 
incorporates one’s illness story over the life course. Corbin and Strauss (1988) identified 
four biographical processes including contextualizing, coming to terms with the illness, 
restructuring one’s self-concept, and recasting one’s biography into the future. 
 
The Illness Trajectory 
 Another study describing chronic illness was conducted by Corbin and Strauss 
(1991). This research explored the chronic illness trajectory as a multidimensional course 
or unfolding of a chronic illness. The term trajectory refers to the course of a chronic 
disease in its different stages and phases. The resulting Chronic Illness Trajectory model 
included the following phases: pretrajectory, trajectory onset, stable, unstable, acute, 
crisis, comeback, downward, and finally, dying. Knowing where a person was in this 
trajectory was information the healthcare provider could use to tailor interventions and to 
support the patient in maintaining his or her quality of life. Corbin and Strauss 
acknowledged that because of the many factors influencing duration and progression 
through the trajectory, the temporality of the trajectory was unpredictable.  
 These works presented foundational knowledge regarding issues, concepts, and 
theories involved in experiences with chronic illness. These included the concept of a 
chronic illness trajectory as an organizational framework for understanding the duration 
and progress of distinct phases involved in the illness experience. The idea that the 
individual is required to do various types of work throughout the illness trajectory was 
also introduced. The possibility of positive outcomes (i.e., self-discovery, living well, 





to with the new self and making new meanings were also presented.  Finally, both Corbin 
and Strauss (Corbin, 1998; Corbin & Straus, 1988; Corbin & Strauss, 1991) and Charmaz 
(1983, 1990, 1997) discussed the impact of multiple influencing factors on the illness 




 The literature reviewed included four qualitative meta-analyses and three 
qualitative analyses of the patient’s experience with chronic illness. Table 2.1 provides 
information about each study’s population, study design and findings. Findings of each 
study are synthesized and presented according to the following headings: phases and 
themes of the illness experience or process, description of the experience or process of 
living with chronic illness, temporality of the experience, influencing factors, and 
implications for nursing.  
 
Phases and Themes 
 Results of my analysis of the seven articles found that the illness experience could 
be categorized into sequential phases or themes. These include becoming aware, focusing 
on illness, reaching a turning point, taking action, trial and error, making adjustments, 
assuming control, and living with chronic illness. 
 
Becoming Aware 
 The process of developing a chronic illness starts with an awareness of the illness. 
The diagnosis was a triggering event for the beginning of a process of change (Dubouloz 
et al., 2010; Hernandez, Antone, & Cornelius, 1999). It was perceived as a life-altering 





(2010) called this the initial response to the diagnosis. This included an emotional 
response to facing a changed life and many personal loses: loss of self, loss of control, 
loss of bodily function and future life activities. Whittemore & Dixon (2008) used the 
metaphor of shifting sands to describe participants’ feelings of uncertainty during this 
phase.  Hernandez et al. (1999) described this time of identity change as “having 
diabetes” that included the “cognitive lifeways” of denying, minimizing and normalizing. 
These ways of thinking could prolong the time an individual was in this phase.  
 
Focusing on Illness 
 Paterson (2001) and Schulman-Green et al. (2012) noted that after a new chronic 
illness diagnosis, individuals experienced a shift in perspective to a focus on illness. 
During this phase, the illness was in the foreground (Paterson, 2001), individuals were 
noted to become absorbed in the illness (the sickness, the suffering, the loss, the burden) 
and could focus on little else.  
 
Reaching a Turning Point 
 Some of the studies found that there was a specific event or catalytic experience 
that occurred, forcing the individual to take an interest in learning about their illness 
(Audulv et al., 2012; Dubouloz et al., 2010; Hernandez et al., 1999; Schulman-Green et 
al., 2012). This turning point was found to be complex and influenced by many factors. 
Schulman-Green and colleagues (2012) noted participants needed to process emotions 
such as grieving for loss of health or function during this phase before they could turn 





perceiving a need to manage the illness before the individual would seek information 
(Audulv et al., 2012).  
 
Taking Action  
 The turning point was the impetus for action. Gerunds were used in almost all of 
the studies to describe this phase: deciding to assume control (Paterson, Thorne, & 
Dewis, 1998), embracing the challenge (Dubouloz et al., 2010), focusing on illness needs 
(Schulman-Green et al., 2012), staying afloat (Whittemore & Dixon, 2008), and seeking 
effective self-management strategies (Audulv et al., 2012). These phases all involved a 
realization that work was needed to be done to begin to understand what it meant to live 
with chronic illness. The new diagnosis created gaps in knowledge and changes in daily 
routines. People with chronic illness sought information about their chronic illness and 
how to manage it to overcome these deficits (Dubouloz et al., 2010; Hernandez et al., 
1999; Paterson, 2001; Schulman-Green et al., 2012; Whittemore & Dixon, 2008). 
 
Trial and Error  
 In the next phase, individuals began to explore and experiment with different 
management strategies (Dubouloz et al., 2010; Paterson et al., 1998). Participants 
contextualized the prescriptive regimens and the new knowledge to their own life to see 
how it fit. They considered costs and benefits of these changes on their quality of life 
(Audulv et al., 2012).  
 
Making Adjustments 
 If the cost of illness management outweighed the benefit, individuals would make 





management, and Schulman-Green and colleagues (2012) called it integrating illness into 
daily life. New coping strategies were developed along with new routines and plans of 
action (Audulv et al., 2012; Whittemore & Dixon, 2008). Socially, individuals made 
changes to activities and in relationships with others in order to fostering supportive, 
constructive relationships (Dubouloz et al., 2010; Paterson et al., 1998; Whittemore & 
Dixon, 2008).  
 
Assuming Control 
 After the individual with a chronic illness went through the trial and error phase 
and the adjustment phase, they became an expert of their own illness management 
(Schulman-Green et al., 2012). During this phase, the assuming control phase (Paterson 
et al., 1998) or the taking care phase (Hernandez et al., 1999), the individual shifts from a 
passive participant in care to an active one.  They form partnerships with their healthcare 
provider (Paterson et al., 1998; Schulman-Green et al., 2012), address challenges, and 
activate resources (Schulman-Green et al., 2012) when needed. This is important as 
Paterson (2001) and Hernandez (1999) noted that the health care provider’s goals of 
management (blood glucose control) can be different from an individual’s goals (quality 
of life).  
 
Living With Chronic Illness 
 Integration of new ways of being (Dubouloz et al., 2010; Schulman-Green et al., 
2012) was a phase of acceptance of the changed self and a changed way of life. 
Participants were able to objectify the body, no longer identifying self with the diseased 





diabetic self with the personal self, as described by Hernandez (1999) and by Dubouloz 
and colleagues (2010).  
 Paterson describes this as a shift in perspectives to wellness in the foreground 
(Paterson, 2001). Participants are able to focus on the emotional, spiritual, and social 
aspects of life, instead of the illness-focused aspects that characterized the illness in the 
foreground perspective. Whittemore and Dixon (2008) call this phase “rescuing oneself 
and navigating life,” and Schulman-Green (2012) called it “living with chronic illness.”  
This period represented a time of re-engagement in a meaningful way of life through 
working at health, participating in life, and connecting with others (Whittemore & Dixon, 
2008).  
 Paterson, Thorne, and Dewis (1998) noted coming to terms with illness led to a 
new way of thinking about self and way of engaging in life that was described as 
achieving a sense of balance. Other studies also observed positive outcomes such as a 
heightened sensitivity to life, appreciation of life and loved ones, adoption of a future-
oriented perspective to life, greater attention to care of the self, greater attention to others, 
renewed or new spirituality, and finding purpose and meaning (Dubouloz et al., 2010; 
Hernandez et al., 1999; Paterson, 2001; Schulman-Green et al., 2012; Whittemore & 
Dixon, 2008). Meaning making in chronic illness refers to the individuals’ efforts to 
determine the meaning of the illness in their lives, reevaluating life, and experiencing 
personal growth and satisfaction (Schulman-Green et al., 2012). 
  
Temporality 
 All studies reported distinct phases of the process a person goes through when 





were varied. Hernandez (1999) and Dubouloz (2010) reported finding a linear, 
predictable, process that could have regressions, but the end goal is reached by 
completing previous stages first before going on to the next. Schulman-Green et al. 
(2012) posited that the emotional processing should precede adjusting, which must 
precede meaning making, but conceded that these probably overlap and interact with 
each other. Both Paterson (2001) and Audulv et al. (2012) described the process as 
shifting, and Whittemore and Dixon (2008) and Paterson et al. (1998) found the 
progression through the process to be nonlinear and unpredictable. 
 
Influencing Factors 
 There were many factors that influenced how people moved through the phases of 
the chronic illness course. These included personal characteristics such as an individual’s 
underlying knowledge, beliefs and attitudes, past life and illness experiences, the 
presence of comorbidities, and financial and social resources (Paterson et al., 1998; 
Schulman-Green et al., 2012; Whittemore & Dixon, 2008). The overall illness experience 
also impacted the course (Audulv et al., 2012; Paterson, 2001; Schulman-Green et al., 
2012). Dubouloz et al. (2010), Schulman-Green et al. (2012) and Paterson (2001) noted 
that the quality of relationship with health care providers (HCPs) was influential on the 
illness experience. 
 Characteristics of the illness such as a progressive or uncertain illness trajectory, 
new symptoms, disease and complications (Paterson et al., 1998) and treatment for the 
illness, and side effects (Schulman-Green et al., 2012) and complexity of the treatment 
regimen (Schulman-Green et al., 2012) were also factors that influenced the illness 





self-efficacy, willingness, and motivation or readiness to progress to the next stage 




 The studies reviewed here added depth and breadth to the earlier works by 
Charmaz (Charmaz, 1983, 1990, 1997) and Corbin and Strauss (Corbin, 1998; Corbin & 
Straus, 1988; 1991). Illness experience was described using multiple constructs such as 
integrating, transforming, shifting of perspectives, balancing, and transitioning. Phases 
and stages of illness were also identified as becoming aware, focusing on illness, turning 
point, taking action, trial and error, adjusting, assuming control, and living with chronic 
illness. The orders of the phases were found to be both linear and non-linear, but all 
agreed the illness course was complex and dynamic. And finally, factors influencing the 
illness experience were noted to be complex and multifactorial, comprosed of personal, 
illness, and social factors.  
 This body of literature presented models, frameworks, and theories that can be 
used to inform patient-centered interventions, assessments, and outcomes measurements 
(Bartholomew, Parcel, Kok, Gottlieb, & Fernandez, 2011). Examples of how they have 
been used can be found in nursing research. For example, The Corbin and Strauss 
Chronic Illness Trajectory has been applied to the nursing process (Corbin & Strauss, 
1991), to develop a framework for self and family management of chronic conditions 
(Grey, Knafl, & McCorkle, 2006), to cancer survivorship (Klimmek & Wenzel, 2012), 
and to metastatic breast cancer (Reed & Corner, 2013). However, not all health care 
interventions are theoretically based. Limitations of applying theories to practice can be 





Implications for Practice 
 How can middle-range theory produced by grounded theory researchers be 
utilized in nursing practice? In this literature review, all of the researchers found that 
effort was involved in the illness experience and this work was similar to Corbin and 
Strauss’ description of the work of chronic illness management (Corbin & Straus, 1988). 
In addition, it was acknowledged that individuals with chronic illness needed support and 
that supportive needs varied depending upon individual circumstances. Whether or not 
the patients were on a linear or nonlinear trajectory, an undisputed implication of the 
studies was that the healthcare provider needed to assess where the individual was 
currently situated, and plan care accordingly. In order to do this, it is possible to look to 
nursing and other health care research findings that provide theoretical or conceptual 
frameworks of the work of chronic illness care at various stages of the illness course and 
interventions that were successful. The nurse or other healthcare provider can apply this 
knowledge to similar populations. For example, a newly diagnosed individual may not 
have accepted his or her new illness yet, or reached the turning point, and not be ready to 
talk about behavior change. Another example, during the illness in the foreground stage 
described by Paterson (2001), patients are focused on illness-related work (i.e., symptom 
management) and therefore interventions aimed at biographical work (i.e., support 




 Research surrounding the development of type 2 diabetes and other chronic 
illnesses was used to understand current concepts and theories surrounding illness 





healthcare team to locate where individuals are in their illness course and to assess their 
contextual factors so that individualized care can be planned accordingly. Through 
research aimed at exploring patients’ concerns and how they solve concerns during each 
phase in different contexts, health care knowledge expands and improves, allowing for 
providers to better align health care strategies with patient needs. The aim of this study 
was to understand the experience of older adult HCT recipients as they develop and live 
with newly diagnosed diabetes. The resulting theory provides health care providers with a 
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fits one’s life 
Description of 
experience: a process of 
self-management 
integration that varied 
within contexts. Shaping 
the integration process 
required individuals to 
take an active part.  
Resulting model: the 
process of self-
management integration. 
Temporality: back and 
forth between phases 
Influencing Factors: 
illness experience, life 
situation, personal beliefs, 
social support 
Implications: HCP should 
provide self-management 
support tailored to the self-
management phase and 
life context 
    Influencing factors: 
social influence-healthcare 
system, significant others 
and healthcare 
professionals and personal 
contexts, the person living 
with the illness, 
willingness, ability, and 
readiness to progress to 
the next stage. 
Implications: Use the 
model of integration to 
locate the person and then 
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of previous self with 
diabetic self.  
Resulting model: Theory 
of Integration 
Temporality: Having 
diabetes-can stay in this 
phase for many years, 
event or other factor 
prompted progression to 




Implications: be cultural 
competent when 

























experience: shifting of 
perspectives between 
illness or wellness in the 
foreground. During 
illness in the foreground, 
the focus is on sickness 
and the suffering, loss, 
and burden the illness 
causes-occurs during new 
diagnosis, new 
symptoms, or acute 
illness. During wellness 
in the foreground, the 
focus is on self more than 
disease, allowing a person 
to focus on the emotional, 
spiritual and social 
aspects of life.  
Resulting model: The 
shifting perspectives 
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                                                                          Phases 
Temporality: nonlinear, 
living with chronic illness 
is an ongoing, continually 
shifting process in which 
the person moves 
between wellness in the 
foreground and illness in 
the foreground 
Influencing Factors: 




should identify and 
understand the current 
perspectives of the 
individual with chronic 


























was learning to balance 
Temporality: decision to 
control can change 
Influencing Factors: 
knowledge, beliefs in 
one’s ability, new 
symptoms, disease and 
complications, life events 
Implications: The HCP 
should asses if the 
individual has decided to 
assume control and what 




















of chronic illness into 
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in phases requiring 
substantial work.  
Resulting model: 




treatment side effects, a 
progressive or uncertain 
illness trajectory, co-
morbidity, depressive 
symptoms, bad days, 
financial hardships, and 
interpersonal/environmen
tal challenges, illness 
experience, resources 
Implications: Illness 





between “living a life” 














































experience: the process 
of self-management 
involved tasks and skills 
similar to Corbin and 
Strauss’ three categories 
of work. Tasks and skills 
were related to coping 
with the illness and 
growing as a person and 
transitioning from focus 
on illness needs to 
integration of the illness 
into the context of the 
individual’s daily life.  
Temporality: 
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factors affecting ability 
and motivation to self-




factors, clinical factors 
such as comorbidities and 
complexity of the 
treatment regime, and 
system factors such as 
quality of relationships 
and communication with 
providers 





that are aligned with what 
is important to the patient. 
Open communication and 
collaboration is 
beneficial. 


























 The research question for this study was, What do middle age and older adults 
experience when they develop new-onset diabetes after just finishing cancer treatments? 
This question was formulated through my professional encounters as a certified diabetes 
educator at an oncology hospital. I met several individuals who were referred to me for 
new-onset diabetes education after HCT. And even though I was exposed to them briefly, 
I was left with the impression that they were unlike other people who had recently 
developed type 1 or type 2 diabetes. They had different questions about their disease, for 
example, they had many questions regarding the relationship between diabetes and 
cancer, cancer survival, and follow-up. These clinical experiences were the impetus for 




Overview of Methodology 
 The method chosen to answer this question was grounded theory (GT). GT is 
based on the theoretical assumptions of symbolic interactionism. Symbolic interactionism 
assumes that people act on the basis of meanings that things have for them, meanings 






practice (Blumer, 1969). GT is a methodology for systematically analyzing human 
experience and how meanings are developed and processed. There are four main 
strategies involved in conducting GT (Charmaz, 2014). The first is inductive reasoning. 
This is a strategy that infers patterns from the data to create theory instead of deductively 
testing a previously developed theory for external validity. Second is comparison. Data 
are compared to data, data with codes, codes with codes, codes with categories, and 
categories with categories throughout the process. Third is the iterative nature of the 
process and development of gathering, analyzing, and interpreting data that occur during 
GT. Lastly, the researcher is interactive and continually involved in data collection and 
analysis. The results of these inductive methods are an empirical theory that is grounded 
in the data and valid to a specific population.  
 Since its inception by Glaser and Strauss (1967) almost a half century ago, 
grounded theory has gone through various iterations and modifications. Today, there are 
two major branches of grounded theory, Glaserian and constructivist grounded theory.  
Glaserian GT is more objectivist and requires researchers to suspend prior knowledge and 
preconceptions in order to allow the emergence of concepts from the data (Glaser, 1978). 
The constructivist viewpoint makes the assumption that truth is co-created through the 
interactive process of researcher and participant constructing a shared reality (Charmaz, 
2000). The resulting theory is an interpretation that depends on the researcher’s view.  
 This study utilizes constructivist grounded theory as it allows for my own 
personal and professional knowledge and experience to be considered. These personal 
qualities change how I interpret, prioritize, and think about the data. This insight is also 





Corbin, 1994). My own knowledge regarding the medical construction of common types 
of diabetes versus postcancer diabetes allowed me to question, observe, and explain 
variations in cancer survivors’ experiences that would not be obvious through participant 
explanation alone.  
 
Setting 
 The setting for this study was a 200-bed National Cancer Institute-designated 
comprehensive cancer center in Southern California that performs over 500 allogeneic 
and autologous transplantations per year. The facility is at the forefront of medical and 
basic science research. 
 
Sample 
 The initial purposive sample included adults above 50 years of age who 
developed new-onset diabetes after they received an allo HCT for treatment of a 
hematological malignancy between 2008-2013. Patients must have had elevations in 
laboratory blood glucose levels during the HCT process or at their first follow-up visit 
consistent with the ADA criteria for the diagnosis of diabetes. These include a fasting 
glucose ≥126 mg/dL, random glucose ≥200mg/dL with symptoms (polyuria, polydipsia, 
or unexplained weight loss) confirmed on two occasions (ADA, 2014). Glycosolated 
hemoglobin (A1C) will not be used for eligibility criteria as an indicator or a marker of 
hyperglycemia based on its questionable reliability in this patient population (ADA, 
2014). Blood glucose elevations, fasting glucose ≥126 mg/dL, random glucose 
≥200mg/dL, and/or the use of antihyperglycemic medications must have been persistent 





assessment at 1-to-5 years post HCT. This time frame allowed the participants at least 
one year or more to have experienced and potentially integrated the diabetes and its 
implications into their lives.  
 Patients were required to be able to read and speak English, able to read and/or 
understand the study protocol requirements and provide written informed consent. Age 
50 years or older was chosen as it represents the new and expanding group of HCT 
patients (National Marrow Donor Program, 2010) who are at risk for diabetes (ADA, 
2014). Patients who had pre-existing diabetes prior to HCT were excluded. Patients with 
advanced or relapsed cancer were also be excluded.  
 To ensure adequate sample size, a query was run using the hospital’s health 
information system to estimate a potential sample size. The number of HCT recipients 
above the age of 50 at this facility during 2011-2012 was 266. It was assumed that an 
adequate sample size would be available, considering a 5-year time period. 
 
Recruitment of Participants 
 After approval from the institution’s Institutional Review Board (IRB) and the 
principal investigator’s university’s IRB, potential participants were identified with the 
assistance of the institutions’ health information services. A list of all allo HCT patients 
above the age of 50 between 2008 and 2013 who did not have a pre-existing diabetes 
diagnosis but had a diagnostic code related to hyperglycemia and/or diabetes during or 
after their HCT process, was requested and obtained. The principal investigator reviewed 
electronic health records of prospective participants to find eligible candidates for the 
study. Those who had persistent hyperglycemia at 1-to-5 years post HCT were 





 One hundred and nineteen recipients met the initial criteria and were screened for 
inclusion.  Of these, 89 were ineligible due to unavailability of current health records or 
no mention of impaired glucose metabolism in the last three available dictations. A total 
of 22 participants remained in the pool of eligible participants who met the purposive 
sampling criteria for this study and were actively recruited for participation. These 
individuals were contacted by the principal investigator over the telephone. Those who 
agree to participate were consented (Appendix A) and asked to schedule a time to meet 
with the principal investigator for an interview. All interviews were conducted over the 




Disease and Demographic Data 
 The disease and demographic data form (Appendix B) was completed by the 
principal investigator prior to the participant interview. Disease and demographic data 
were used to enrich participant description.  
 
Unstructured Interviews 
 The interview began with a broad question, “Tell me about your experience with 
high blood sugars after your transplant.” Morse (2001) found that this question usually 
leads to a sequential telling of the patient’s experience from the beginning of the 
narrative. Additional probes the interviewer may use to stimulate the participant to tell 
their story included:  
1. What happened next? 
2. Tell me how how diabetes has been part of your illness experience? 






Interviews are expected to take one to two hours. Patients showing signs of fatigue were 
asked if they would like to take a break, or if they would like to reschedule the interview 




 Interviews ranged from 22 to 82 minutes. Each interview was digitally recorded 
and transcribed verbatim by a HIPAA-certified transcriptionist who had signed a 
confidentiality agreement with the investigator. As each transcript was returned, the 
investigator verified the accuracy of the transcript with the audio recording and 
reconciled any discrepancies in the transcription. The transcribed document was uploaded 
into coding software (Atlas.ti, 2009).  
 The constant comparative method of grounded theory was used to simultaneously 
collect, code, and analyze the data (Charmaz, 2006; Glaser, 1978). As indicated by the bi-
directional arrows in Figure 3.1, data analysis in grounded theory is not a linear process. 
During the coding process, the researcher constantly compares labels to emerging 
concepts, then relating concepts to other concepts and properties. Coding is an iterative 
process of moving back and forth between the data, constantly comparing codes, 
categories, and themes to one another and then renaming as needed (Glaser & Straus, 
1967).  
 Analysis began with Open Coding as a first-cycle coding method. This involved 
reviewing the transcript line-by-line, breaking it down into discrete parts (or incidents), 
and labeling each line with a code. Both In Vivo and Process Coding were used in the 
first-cycle coding process. In Vivo coding involves using participants’ own words as a 





data. The codes generated in Process Coding often reflected sequential phases of a 
process (Saldana, 2013). 
 Second-cycle coding allows for reorganizing and reanalyzing data collected 
during first-cycle coding (Saldana, 2013).  Axial and Focused Coding was employed 
during second-cycle coding. During second-cycle coding, first-cycle codes are 
reorganized by renaming them to more accurately reflect the data and merging codes that 
are redundant. Also, codes that are most frequent or significant are identified and sorted 
into thematic or conceptual categories. 
 First-cycle and second-cycle coding continued sequentially after each interview 
was transcribed. After the first 8-10 interviews, most of the categories were identified. At 
this point, some structured interview questions where developed to explicate categories 
more fully. For example, participants were asked how they found out they had high blood 
sugars in order for the author to better understand the communication of and depth of 
knowledge about diabetes. 
 Salient categories emerged during second-cycle coding, reflecting phases and 
sequences in a process amenable to conceptual diagramming or clustering (as described 
by Charmaz, 2006).  I augmented coding with diagramming to depict the relationship of 
phases and sequences as part of the overall experience. Flow diagrams were written on 
large sticky notes posted on a wall to better visualize relationships between the thematic 
or conceptual categories. This allowed me to purposefully and iteratively use both 
clustering and focused coding to reanalyze and reorganize the data as I continued to 





 Throughout the coding and diagram process, I wrote analytical memos to record 
insights, concerns, and hypotheses about potential relationships among quotes, codes, and 
categories. Each flow diagram, emerging from current memo and data analysis, proposed 
a process composed of thematic categories as stages. To ensure validity in the theorizing 
process, each version of the overall theory was subjected to examination against the 
actual data.  For example, with each new diagram and evolving version of the grounded 
theory, the researcher asked, “Would most of the participants agree with this depiction of 
the process of developing new-onset diabetes after allo HCT for the treatment of 
hematological cancer?” If not, exceptions to the emerging theory and examples of 
maximum variation were rescrutinized and the theory refined to capture exceptions and 
retheorize with additional context, conditions, and consequences. As more memos were 
written, thematic categories (aka stages) were delineated and reorganized, and a new 
diagram was proposed that detailed the process and stages of the theory. This iterative 
process of diagraming, checking for fit, and memoing resulted in one final theory with 
three divergent trajectories. To compare and contrast these three trajectories, two tables 
were created that delineated the properties and dimensions of stages that were common to 
all participants and those that diverged.   
 
Issues of Trustworthiness and Rigor of Qualitative Data 
 There is little disagreement amongst qualitative researchers about their need to be 
held to the same standards as all other researchers in order to advance science (Morse, 
1999; Whittemore, Chase, & Mandle, 2001). Reliability and validity as measured in 





Glaser and Strauss (1967, pp. 237-250) and Glaser (1978, pp. 4-6) set forth the following 
criteria as standards by which the grounded theory should be assed: 
1. Fit: the conceptual codes and categories emerge from the data and not 
preconceived codes or categories from prior knowledge. 
2. Work: refers to how well the grounded theory explains behavior in the substantive 
area and how well it can predict future behavior 
3. Relevance: how well does the theory focuses on a core concern or process of those 
being studied.  
4. Modifiability: does the theory lend itself to being modified as new data emerge to 
produce new categories, properties or dimensions of the theory. 
 
Fit, work, relevance, and modifiability were assured through the process of constant 
comparison.  Data from one participant were compared to data from another, codes were 
compared to codes, and categories to categories with more refinement after each 
interview. In addition, the emergent theory was constantly compared within and between 
participants to ensure fit. Practitioners with experience in managing diabetes in people 
with and without cancer were also asked to weigh in on the fit of the final theory. The 
group agreed the theory was aligned with the experience they observed in clinical 
practice. Senior qualitative researchers were included as members of the research team 
and provided consultation and methodological support during each phase of the study. In 




 The study was reviewed and approved by the study site’s IRB.  The University of 
Utah IRB considered the study minimal risk and determined this study exempt. To ensure 
ethical issues in research were upheld, all research personnel underwent training in the 






Potential Risks and Protection against Risks 
 
 A potential risk to participants was breech of privacy. Research materials obtained 
from subjects consisted of disease and demographic data and recorded and transcribed 
interview data. All data were collected solely for the use of this study, and only myself 
and research personnel had access to private information pertaining to subjects enrolled 
in the study. All data was collected by me during in-person encounters or over the 
telephone. Privacy was provided for all data collection. Participation in this study was 
voluntary and all data were kept anonymized and confidential.  All names or other 
protected information were not used. All study files are maintained in password-protected 
computers or locked file cabinets, both kept behind locked doors.  Audiotapes from the 
interviews will be destroyed 1 year after publication of results.   
 Although none of the participants in this study experienced distress from 
discussing their experience and confidentiality, a mechanism was in place for referral of 
the patient back to their primary oncologist if the need had arisen.  
 
Recruitment and Informed Consent 
 
 Written consent, approved by the study site’s IRBs, was obtained from all 
subjects. The consent was reviewed with participants to ensure they understood the 
nature of their participation and the duration of the study. I reviewed data collection 
methods, the time required, and potential risks. Participants were given the opportunity to 
ask questions, and were informed they could withdraw from the study at any time without 
repercussions. Participants were informed of potential benefits of participating in the 
study, including recognition of the patient experience of developing long-term chronic 





Furthermore, they were informed that this information may also benefit future older adult 
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Figure 3.1 A model for development of grounded theory. Copyright© Johnny Saldana.  












DEALING WITH NEW-ONSET DIABETES AS A LONG-TERM EFFECT  
OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION  





 Currently, little information is available to guide health care practitioners on how 
to best support middle age and older adults who developed new-onset diabetes after 
allogeneic hematopoietic cell transplantation (allo HCT) for treatment of hematological 
cancers. Results from this constructivist grounded theory study provide a theoretical 
framework of the psychosocial process of change that occurred in this substantive cohort. 
Stages of the theory included 1) finding out about diabetes, 2) formulating an 
understanding of diabetes in relation to cancer, 3) formulating a diabetes identity, and 4) 
dealing with diabetes after cancer. There were three distinctive patterns of movement 
through the stages of the theory dependent on how individuals recovered from the cancer 
treatment. The variant pattern groupings were 1) recovery with no or minimal 
complications from the allo HCT, 2) recovery complicated by intermittent difficulties, 
and 3) ongoing complications.  While the group with few complications was able to 
integrate diabetes self-management into everyday life, the other groups had different 
responses primarily attributed to graft-versus-host disease and steroid use. The theory 






affected how individuals identified with and prioritized diabetes. Implications for practice 
are 1) assess and provide ongoing supportive interventions for the work of cancer 
treatment complications, 2) assess diabetes beliefs and correct inaccuracies, and 3) 
develop a consensus on the definition and treatment guidelines of new-onset diabetes 
after allo HCT to facilitate patient-provider communication, diabetes self-identification, 
and adaptation to diabetes.1  
 
Introduction 
 In this study, we explored how middle age and older adults (> 50 years), who 
survived hematological cancers by receiving treatment with allogeneic hematopoietic cell 
transplantation (allo HCT), experienced the subsequent development of new-onset 
diabetes. Studying the course of illness over time can offer health care providers (HCPs) 
information needed to guide patient-centered interventions. Grounded theory 
methodology is ideally suited to explore the process of change that occurs when 
individuals develop a chronic change in health. 
 
Background and Significance 
 In middle age and older adults with hematological cancers, a potential curative 
treatment is allogeneic hematopoietic cell transplantation (allo HCT). Each year over 
10,000 allo HCTs are performed in the U.S. annually (Pasquini & Wang, 2013). Among 
the more than 41,000 survivors of allo HCT, 36% are above 50 years of age and 16% are 
above 60 years of age. These numbers are expected to increase 2.5-fold by 2020 and 5-
fold by 2030 (Pasquini & Wang, 2013). These allo HCT recipient hematological cancer 
                                                





survivors are at risk for type 2 diabetes, hereafter referred to as diabetes. One risk factor 
for diabetes in this patient population is age. The prevalence of diabetes in older adults 
 (above 65 years) is greater than 25%, compared to the general population prevalence of 
9.2% (Centers for Disease Control and Prevention, 2014a). Diabetes is also a risk for 
cancer (Giovannucci et al., 2010). Recent findings indicate that diabetes occurs more 
frequently, at rates as high as 18%, in individuals with comorbid cancer (Barone et al., 
2010). Treatments associated with allo HCT also increase risk for diabetes. Diabetes has 
been found to occur as a late effect of treatments 3.65 times more often than in a matched 
cohort of non-allo-HCT adult recipients (Baker et al., 2007). 
 Diabetes can occur as a pre-existing condition, as a late- or long-term effect of 
treatments, or as a natural progression unrelated to treatments (Figure 4.1).  This study 
specifically targeted individuals who developed diabetes after their allo HCT. The allo 
HCT trajectory is described below to enhance understanding of how individuals perceive 
and responded to diabetes. 
 
The Development of Hematological Malignancies, Treatment  
With Allo HCT, and Risk for Diabetes 
 The bone marrow is responsible for hematopoiesis, or the production of the cells 
of the blood. The pluripotent hematopoietic stem cells, under the influence of tissues and 
hormonal factors, differentiate and mature into red blood cells, white blood cells, and 
platelets (Ezzone, 2013). This process can be damaged through bone marrow failure, 
destruction of marrow by disease, and chemotherapy and radiation. Disorders of the bone 
marrow can be malignant as observed in leukemia, multiple myeloma, myelodysplasia, 





(Appelbaum & Thomas, 2009). To treat these hematological conditions, hematopoietic 
stem and progenitor cells acquired from healthy individuals can be transplanted into 
affected individuals. These donor cells are able to home to the bone marrow, self-renew, 
and reconstitute within the bone marrow, thus leading to the production of healthy 
immune cells. The functional immune cells being reconstituted from the matched donor 
cells will then be able to appropriately detect and eliminate foreign microorganisms, 
prevent proliferation from any newly forming aberrant cells, and repair tissue damage 
(Ezzone, 2013)  
 Traditionally, the population with the greatest prevalence of hematological 
cancers, middle age and older adults, was excluded from treatment with allo HCT 
because of their inability to tolerate the intensive required pretransplantation 
chemotherapy conditioning regimen and associated toxicities. However, advances in 
HCT science, such as modified conditioning regimens, have decreased HCT-related 
morbidity and mortality, allowing middle age and older adults to also consider this 
potentially curative treatment option (Popplewell & Forman, 2002). As a result, adults 
over 50 years of age are currently the fastest growing segment of the allo HCT population 
(Pasquini & Wang, 2013).  
 The treatment phases of allo HCT vary based on underlying disease, treatment, 
and patient characteristics, but usually include 3 acute phases (conditioning, transplant, 
pre-engraftment) followed by reconstitution or recovery phase. During the acute phases, 
prior to the engraftment and reconstitution of humoral immunity, patients are at high risk 
for adverse complications. The majority of middle age and older adults are therefore 





donors’ cells occurs at around 3-4 weeks (Ezzone, 2013). Full recovery of the patient’s 
immune system varies depending on patient, disease, and donor characteristics and can 
take up to a year in some individuals. Therefore, patients must continue frequent 
surveillance and immune precautions. Despite all the advances in transplantation science 
and rigorous follow-up protocols, morbidity and mortality rates continue to be 
substantial. Complications such as graft-versus-host disease (GVHD), when the donor 
immune system detects the host tissue as foreign and attacks it, and infection are the 
second (19%) and third (17%) leading causes of death after allo HCT respectively, 
following only primary disease as the first (38%) cause (Pasquini & Wang, 2013).  
 Hyperglycemia has been shown to contribute to these adverse effects of allo HCT 
recipients in people with and without diabetes and is therefore important to identify and 
control to improve both short- and long-term patient outcomes (Armenian et al., 2012; 
Olausson et al., 2014). During the inpatient phases, most patients (70-90%) will 
experience hyperglycemia secondary to the stress of acute illness or as a side effect of 
adjunctive HCT treatments such as glucocorticoids (hereafter referred to as steroids), 
calcineurin inhibitors, and parenteral nutrition (Olausson et al., 2014). In the majority of 
cases, blood glucose levels revert to normal after HCT, but some individuals will 
continue to experience hyperglycemia. Figure 4.1 shows the constructed presentations of 
diabetes during the allo HCT trajectory. 
 This persistent hyperglycemia has not been medically constructed, meaning a 
definitive diagnosis and treatment guidelines have not been established. There is no 
distinct point in time when post-allo-HCT hyperglycemia transitions to new-onset post-





levels; abnormal readings confer a diabetes diagnosis (ADA, 2015). Glycosylated 
hemoglobin tests (or A1c) are useful to discern acute versus chronic hyperglycemia, but 
this does not differentiate long-term induced diabetes from frank or overt diabetes. 
Therasse and colleagues (2013) consider these factors in their recommendation to delay 
the diagnosis of new-onset diabetes in solid organ transplantation recipients until 
transient causes, such as steroid use, parenteral feedings, and acute illness are resolved. 
This recommendation has not widely been adapted to the solid organ or the HCT 
populations. Clinically, this is an important distinction to make because some 
hyperglycemic conditions presumed to have short duration are not adequately treated 
(Clore & Thurby-Hay, 2009).  
 In addition, differentiating transient hyperglycemia from overt diabetes has 
epidemiological importance. Griffith, Jagasia, and Jagasia (2010) have reported 
prevalence as 30% at 2 years and 3.3% at 6 years after allo HCT. This report, however, 
does not parse differences in prevalence between diabetes as a transient versus permanent 
condition. As of yet, no clear definition or treatment guidelines have been developed for 
new-onset diabetes after allo HCT. Instead, guidelines put forth for people with in the 
general population with diabetes (ADA, 2015) are suggested (Griffith et al., 2010).  
   
Relevant Allo HCT and Diabetes Psychosocial Experiences 
 Studying a person’s perception of the illness experience can facilitate the 
healthcare team’s empathy and proactive efforts to help patients negotiate their way 
through the experience of chronic illness and long-term treatment (Martin & Peterson, 
2009). To our knowledge, the experience of middle age and older adults developing new-





individuals in the lateral populations are reviewed here. 
 
Chronic Illness Experience 
Previous research on chronic illness has demonstrated that when an individual 
develops a chronic condition, he or she goes through a psychosocial process of change. 
Through their research on the chronically ill, Corbin and Strauss (1988) developed the 
Chronic Illness Trajectory, an organizational framework for understanding the duration, 
transition, and progress of distinct phases involved in the illness experience. The idea that 
the individual is required to do various types of work throughout the illness trajectory 
was also introduced. Illness-related work included tasks necessary to manage or treat a 
chronic illness and its sequelae. Everyday life work was defined as the daily activities of 
living in society. Biographical work refers to defining and maintaining an identity that 
incorporates one’s illness story over the life course. Also presented were the possibility of 
positive outcomes (i.e., self-discovery, living well, balance) as a result of going through a 
process of restructuring identity, coming to terms with the new self, and making new 
meanings.  Finally, both Corbin and Strauss (Corbin, 1998; Corbin & Straus, 1988; 
Corbin & Strauss, 1991) and Charmaz (1983, 1990, 1997) discussed the impact of 
multiple influencing factors on the illness trajectory. 
  
The Experience of Becoming an Allo HCT Survivor  
 Although there are some commonalities in the experience of developing a chronic 
illness, there are differences specific to each chronic illness. The experience of having 
and being treated for cancer is like no other. Cancer has an effect on individuals, not only 





Stovall, 2006). The diagnosis of cancer forces individuals to consider the inevitability of 
their own death (Lee & Loiselle, 2012). Treatment for hematological cancers vary based 
on the underlying illness. Allo HCT can be offered as first-line treatment for some 
malignancies, but is more often considered for recalcitrant or relapsed disease. Having to 
choose whether to undergo a treatment that is associated with substantial mortality and 
physical and psychosocial morbidity, was found to evoke feelings of stress, uncertainty, 
and anxiety (Haberman, 1995; Xuereb & Dunlop, 2003).  
 Studies exploring the hospitalized treatment phase of allo HCT and transition 
back to independence have described both phases to be fraught with psychological 
stressors. Klimmek and Wenzel (2012) provide insight to the lines of work specific to the 
phases of cancer survivorship. Most of these concerns decreased over time, and by 3 
years after allo HCT, the majority of older adult cancer/allo HCT survivors reported good 
to excellent quality of life despite continued physical and psychosocial sequelae (Ezzone, 
2013; El-Jawahri et al., 2014). Severity of GVHD is reported as the greatest moderator 
associated with quality of life (Pidala et al., 2011). 
 Rationale for this increase in reported quality of life in response to the 
psychosocial trauma and existential concerns associated with cancer has been explained 
by the adaptive mechanism of meaning making. This has been described in the general 
population of cancer survivors (Halldorsdottir & Hamrin, 1996; Lee, 2008; Park, 
Edmondson, Fenster, & Blank, 2008) and in allo HCT recipients (Johnson Vickberg et 
al., 2001; Tierney, Facione, Padilla, & Dodd, 2007; Xuereb & Dunlop, 2003). Positive 
growth resulting from the meaning making process included enriched appreciation of life 





Johnson-Vickberg and colleagues (2001) demonstrated that allo HCT recipients were 
able to find global meaning, defined in this study as the general sense that one's life has 
order and purpose, in their experiences. The process of meaning making was found to 
begin after the threat of cancer was diminished when individuals shift from a focus on 
illness (as described by Paterson, 2001) to reflection on the effect of cancer on their lives 
and an understanding of the world and their place therein (Park et al., 2008). 
 
The Experience of Developing New-onset Type 2 Diabetes 
 In diabetes, the majority of which is found among older adults, qualitative 
research has shown the trajectory to be made up of various stages from prediagnosis to 
adaptation. These included suspecting and becoming aware of the diagnosis, searching 
for meaning within the diagnosis, accepting the diagnosis and coming to terms, and 
finally, a turning point or shift to illness integration and self-management (Hörnsten, 
Jutterström, Audulv, & Lundman, 2011). A major factor that influenced the process of 
developing diabetes and progressions between the stages, was the individual’s perception 
of the condition.  
 The perception of what caused the illness was shown to have a substantial 
influence on the diabetes trajectory. Because diabetes is often represented as a self-
induced disease caused by unhealthy lifestyles, many people with diabetes feel they are to 
blame for their disease (Broom & Whittaker, 2004). The degree to which people felt 
morally responsible for their diabetes influenced their subsequent self-management 
behaviors. For some, a high degree of blame was a catalyst to change and maintain 
behaviors so they could mitigate future complications (Whittemore, Chase, Mandle, & 





as people tried to protect themselves from the stigma associated with having diabetes 
(Broom & Whittaker, 2004). This was done by shifting the blame for diabetes from 
themselves to other biomedical causalities, such as aging, stress, and genetics (Broom & 
Whittaker, 2004; Hörnsten et al., 2011). Broom & Whittaker (2004) discussed how this 
distancing of self from diabetes may have undermined self-management agency in their 
study participants. Others had difficulty identifying with the diabetes stereotype, such as 
individuals who were of normal weight (Broom & Whittaker, 2004) and those who had 
ambiguous impaired glucose metabolism diagnoses like borderline diabetes and 
prediabetes (Middleton, LaVoie, & Brown, 2012).  
The perceived seriousness of diabetes also influenced the trajectory of type 2 
diabetes. Those who perceived diabetes as a serious threat experienced existential plights 
and strong emotional responses to the diagnosis more so than those who normalized or 
minimized the threats of type 2 diabetes (Broom & Whittaker, 2004; Hörnsten et al., 
2011). High threat was associated with expressions of fear regarding how their projected 
future lives would be affected by having the condition (Whittemore et al., 2002). This 
fear had a positive effect of motivating some people to learn more about their illness and 
make lifestyle changes, while denial or repression of emotions could hinder healthy 
changes (Whittemore et al., 2002). Lower emotional response, secondary to low 
perceived severity of type 2 diabetes, was also associated with individuals being more 
present-oriented and less concerned about performing disease management strategies 
aimed at preventing future diabetes complications (Hörnsten et al., 2011). 
The perceptions regarding the cause and severity of the condition ultimately 





turning point when people seem to emotionally and existentially integrate diabetes and 
self-management strategies into their lives. After accepting the diagnosis of diabetes as a 
chronic condition, they were able to adapt to an altered lifestyle. Those who perceived 
diabetes as low severity or low existential threat had a low emotional response. They also 
prioritized personal goals over self-management care. These individuals were unable to 
reach the turning point to integration of illness and self-management.  
 
The Experience of Developing New-Onset Diabetes After Allo HCT 
 The experience of developing diabetes in the context of allo HCT treatments has 
not been explored. Because new-onset diabetes after allo HCT occurs in the context of 
treatment(s) for a life-threatening illness and has an ambiguous onset, it is conceivable 
that the experience of developing diabetes is quite different for this group when 
compared to the experiences of developing the more common types of diabetes, type 1, 
type 2 diabetes, and gestational diabetes.  Older adult allo HCT recipients with diabetes 
may have very distinct health care needs related to their unique illness experience and 
developmental stages therein. Adding this information to the HCT knowledge base is 
vital to planning holistic care for this cohort. 
 The primary objective of this grounded theory study was to explore the 
experience of middle age and older adults when developing new-onset diabetes after allo 
HCT for the treatment of hematological cancer. Understanding this process and the 
critical junctures that occur during the process will facilitate holistic and humane health 








 Constructivist grounded theory provided the methodological structure for 
developing a mid-range theory from analysis of interview data. Grounded theory is based 
in interpretivist epistemology with roots in symbolic interactionism which assumes that 
one’s reality is created by his or her experience and understanding of the world. 
Grounded theory is a method for understanding these complex and multiple realities. 
Constructivist grounded theory builds on this foundation by recognizing individual 
realities and strives to understand how individuals interpret their own experiences 
(Charmaz, 1990, 2000, 2014). These experiences are interpreted through the lens of the 
researcher, who deconstructs and reconstructs data from multiple participants into 
abstract theory. 
 All people who have gone through cancer treatments and then developed diabetes 
have been through some sort of illness course over time. The aim of this study was to use 
constructivist grounded theory to understand how individuals who developed diabetes 
after cancer treatments interpret and make meaning of their experience. The resulting 
theory, grounded in the data, may be used as the basis to improve healthcare interventions 
for this group. 
 
Participants 
The purposive sample for this study was selected from a 200-bed hospital in 
Southern California. Following approval by the appropriate Institutional Review Boards, 
potential participants were identified from a list generated from the hospital’s health 
information services department that included all allo HCT patients above the age of 50 





HCT process, but had one or more International Classification of Disease (ICD)-9 codes 
related to primary and/or secondary diabetes after their transplantation. To ensure the 
presence of persistent diabetes, participants were required to have recent follow-up at the 
institution. The last three health care providers’ office visit dictations were reviewed to 
confirm notation of diabetes. Patients were required to read and speak English. Age 50 
years of age or older was chosen as a purposeful age range for participants, as this age 
group represents an expanding group of HCT patients (National Marrow Donor Program, 
2010) who are at risk for diabetes (American Diabetes Association, 2014b). Patients with 
advanced or relapsed cancer were excluded from the study, as their experience would 
differ from the social psychological process of adjusting to diabetes after HCT for middle 
age and older adults who experienced effective cancer treatment. 
One hundred and nineteen patients met the initial criteria and were screened for 
inclusion.  Of these, 89 were ineligible due to unavailability of current health records or 
no mention of impaired glucose metabolism in the last three available dictations. A total 
of 22 participants remained in the pool of eligible participants who met the purposive 
sampling criteria for this study and were actively recruited for participation. 
 
                                               Data Collection 
Data were collected over a 4-month period and included participant interviews 
and clinical and demographic information. Prospective participants were contacted by 
telephone, details of the study were described, and if the participant agreed to take part in 
the study, a mutually agreed upon interview time was determined. Nineteen participants 
agreed to be in the study and completed interviews. Thirteen participants were males and 





included acute myeloid leukemia (6), Non-Hodgkin lymphoma (5), myelodysplastic 
syndrome (4), myeloma (2), acute lymphoblastic leukemia (1), and other rare 
hematological malignancies (1). Seven participants had sibling donors and the remaining 
12 had donors who were unrelated. The average time from the allo HCT (day 0) until the 
day of the interview was 3.89 years, with a standard deviation of 1.64. 
 All participants preferred to conduct the interview via the telephone and consents 
were mailed to participants. Once consents were returned, clinical and demographic data 
were abstracted from the patients’ electronic medical record (EMR) by the researcher and 
then participants were telephoned at the agreed upon interview time. 
 Unstructured interviews began by asking participants “Tell me about your 
experience of having high blood sugars after your transplantation.” Interviews ranged 
from 22 to 82 minutes. Each interview was digitally recorded and transcribed verbatim by 
a HIPAA-certified transcriptionist who had signed a confidentiality agreement with the 
investigator. As each transcript was returned, the investigator verified the accuracy of the 
transcript with the audio recording and reconciled any discrepancies in the transcription. 
 
Data Analysis 
 The constant comparative method of grounded theory was used to simultaneously 
collect, code and analyze the data (Charmaz, 2014; Glaser, 1978). After each 
transcription was completed, it was entered into a coding software program (Atlas.ti, 
2009). Analysis began with open coding as a first cycle coding method. This involved 
reviewing the transcript line-by-line, breaking it down into discrete parts (or incidents), 
and labeling each line with a code. Both In Vivo and process coding were used in the 





and at others, action words, or gerunds, were used to code sections of data (Saldana, 
2013). Next, second-cycle focused coding was used to organize first-cycle codes. First-
cycle codes were renamed to more accurately reflect the data, redundant codes were 
merged, and codes with similar properties were identified and sorted into thematic or 
conceptual categories. First-cycle and second-cycle coding continued sequentially after 
each interview was transcribed.  
 After the first 8-10 interviews, most of the categories were identified. At this 
point, some structured interview questions were developed to explicate categories more 
fully. For example, participants were asked how they found out they had high blood 
sugars in order for the author to better understand the communication of and depth of 
knowledge about diabetes. 
 Salient categories emerged during second-cycle coding, reflecting phases and 
sequences in a process amenable to conceptual diagramming.  The first author (JO) 
augmented coding with diagramming to depict the relationship of phases and sequences 
as part of the overall experience. Flow diagrams were written on large sticky notes posted 
on a wall to better visualize relationships between the thematic or conceptual categories. 
This allowed JO to purposefully and iteratively use both diagramming and focused 
coding to reanalyze and reorganize the data as she continued to abstract the basic 
processes and sequences from the data.  
 Throughout the coding and diagram process, JO wrote analytical memos to record 
her insights, concerns, and hypotheses about potential relationships among quotes, codes, 
and categories. Each flow diagram, emerging from current memo and data analysis, 





theorizing process, each version of the overall theory was subjected to examination 
against the data themselves.  For example, with each new diagram and evolving version 
of the grounded theory, the researcher asked, “Would most of the participants agree with 
this depiction of the process of developing new-onset diabetes after allo HCT for the 
treatment of hematological cancer?” If not, exceptions to the emerging theory and 
examples of maximum variation were rescrutinized and the theory refined to capture 
exceptions and retheorize with additional context, conditions, and consequences. As more 
memos were written, thematic categories (aka stages) were delineated and reorganized, 
and a new diagram was proposed that detailed the process and stages of the theory. This 
iterative process of diagraming, checking for fit, and memoing resulted in one final 
theory with three divergent trajectories. To compare and contrast these three trajectories, 
two tables were created that delineated the properties and dimensions of stages that were 
common and different in participants.  
 
Rigor 
 Reliability and validity were assured through the process of constant comparison.  
Data from one participant were compared to data from another, codes were compared to 
codes, and categories to categories, with more refinement after each interview. The 
emergent theory was constantly compared within and between participants to ensure fit. 
Constructivist grounded theory recognizes the importance of the clinical knowledge and 
expertise of the researchers to facilitate explanation of what participants are describing 
(Charmaz, 2014). One of the researchers (JO) worked as a diabetes educator for 2 years 
and then as a predoctoral fellow in the hospital’s diabetes department. Knowledge 





staff endocrinologist and used to explain and assess the emergent theory. Two diabetes 
educators employed at the institution, with experience managing diabetes in people with 
cancer, were also asked to weigh in on the fit of the final theory. They agreed the theory 
was aligned with the experience they observed in clinical practice. Methodological rigor 
was ensured through frequent consultations with senior qualitative researchers as 
members of the research team (LC, JM) during each phase of the study.  In addition, an 
audit trail of detailed memos was kept.   
 
Results 
 The purpose of this study was to explore the experiences of those with diabetes as 
a persistent, long-term effect of allo HCT. Due to the complexity of diabetes occurring 
after allo HCT and lack of a diagnosis specific to this type of diabetes (i.e., ICD-9 codes), 
this study included individuals with diabetes as both an acute, transient condition in 
addition to those with a chronic, persistent condition. The difficulty of identifying 
research subjects with poorly constructed medical diseases is discussed in a separate 
manuscript. The strength of including both chronic and temporary diabetes allowed for 
differences between the groups to emerge during data analysis. The category of most 
theoretical and clinical interest, those with long-term diabetes, was numerically best-
represented in the sample (n=11) and therefore was the most fully described group of 
participants and the primary focus of the study results. The less complicated patterns 
(those with fewer complications after allo HCT recovery) were fewer (n=4 in both 
groups). 
 The majority of participants, regardless of their diabetes status, had similarities in 





are of contextual import to the resultant grounded theory, and were, therefore, included as 
prestages. These stages are described below, followed by the stages of the theory of 
dealing with new-onset diabetes as a long-term effect of allo HCT. Throughout the results 
section, all quotations indicate participants’ own words.  
 
Prestages: Cancer and Cancer Treatments Experience 
 Participants all vividly described finding out about cancer, or “the earth-shattering 
moment when the doctor got up and closed his door before delivering the news about 
having cancer” and being told of how much time they had left to live. The participants 
also told about their prior treatments, the successes and failures, and then the eventual 
decision to undergo a high-risk allo HCT treatment that, as one participant put it, “was 
designed to kill you then bring you back to life.” 
  The average length of the inpatient treatment phase was 42 days. Discussion of 
this phase was described by participants as difficult to remember or “foggy.” The 
following comments illustrated participants’ inability to concentrate, organize care, and 
remember events.  
I was kind of in a fog. I mean Dr. X would come into my room and then she 
would leave and my husband would ask me what she said, and I would say, “I 
don’t know.” And then he would have to call her. I couldn’t concentrate on 
anything. 
 
…..you’re sick, you’re not normal, you don’t think normally. I bought an iPad to 
bring into the hospital to pay bills and that kind of stuff. It was the biggest joke, I 
couldn’t even figure the iPad out for like 6 or 8 months. 
 
 While there was some recollection of having high blood glucose levels during the 
inpatient phase, participants framed hyperglycemia as a side effect that they associated 





asked about communication regarding diabetes during their hospitalization, one 
participant stated they received diabetes education before discharge, while another said, 
“I don’t think anyone cared about diabetes, because my blood sugars weren’t that high.”  
 After discharge was demarcated as a time of continued efforts required by 
participants to recover. To prevent and treat complications, their post-HCT health status 
was monitored closely. This meant frequent interactions with the health care system, 
including outpatient visits, diagnostics, and continuous changes in their medical plan. 
Participants cited complex follow-up care as being “a burden” for themselves and their 
caregivers. All participants described having some degree of post-allo-HCT 
complications or side effects that imposed physical and psychosocial issues. 
Complications after hospitalization included primarily infections and GVHD, while side 
effects were fatigue, dysgeusia (a change in the sense of taste), and weight loss. The 
average reported weight loss described by participants was 30 pounds. In addition, 
adverse physical effects of treatment, the isolation imposed by infection precautions after 
discharge, described by one participant as “basically being a hermit for many months,” 
caused loneliness and a disruption in social roles.   
 When the researcher (JO) asked about how they experienced diabetes during this 
acute recovery time, participants had little recollection. A few participants stated that 
their nutritional priority during this time was to find foods that were palatable—“that 
didn’t taste like burnt rubber.” Only one of the participants remembered being on a 
prescribed diet: a low bacterial diet. None of the participants remembered being told to 
change their eating or exercise patterns to self-manage diabetes during this time. Some 





from the steroids because whenever they increased them for whatever reason, like GVHD 
or pneumonia, or anything like that, my blood sugars went up.” The majority of the 
participants did not remember details regarding having high blood glucoses levels, self-
monitoring blood glucose, or taking diabetes medications. One participant stated, “And 
then I went home, and, I think I was on a medication for my blood sugars. I was on so 
many medications, I can’t remember the names of them all.” And another stated, “I don’t 
really remember, I probably was but I don’t think….I wasn’t religious about doing my 
blood sugar checks. I am not sure I was real good about it.” What participants did 
remember about diabetes self-management was that it was part and parcel of the cancer 
recovery-related work.   
 Despite the described “hell” imposed on participants by the medical treatments, 
they each reflected back on their experience and felt grateful. They were glad they 
survived the allo HCT process and “beat the odds” and expressed profound gratitude for 
their survival. As shown by this participant’s quote, “so I thank God, the Universe, I 
thank everyone I can for making it possible, making it happen every day for what I get to 
experience.” Gratitude towards the staff at the transplant center for their expertise and 
caring was abundant among the narratives. 
 
The Stages of the Theory of Dealing With Diabetes as a Long-term 
Effect of Allo HCT 
 It was not until participants were recovering from the allo HCT that the 
experience with developing diabetes began. The theory of dealing with new-onset 
diabetes as a long-term effect of allo HCT explicates the stages of this experience. These 





relation to cancer, 3) formulating a diabetes identity, and 4) dealing with diabetes after 
cancer.  The most influential variable predicting how groups of people moved through 
these stages was the status of their recovery from their allo HCT. Three patterns of 
movement through the stages of the theory were noted. While there were a variety of 
complications, the primary complication was GVHD. Table 4.1 illustrates the 
characteristics of the three emergent groups.  
 
Group One: The No or Minimal Complications Group 
 Participants who recovered from allo HCT with minimal complications were able 
to discontinue or minimize cancer-related treatments and interventions. Continued side 
effects, such as hyperglycemia, were no longer attributable to cancer treatments, such as 
steroids. This group stated that they found out that they had diabetes via clear 
communication from their primary care providers, often confirmed by laboratory results. 
The following quote demonstrates how initially high blood glucose levels were attributed 
to steroids, but because hyperglycemia persisted after the treatments were discontinued, a 
diabetes diagnosis was conferred. As one participant stated, 
When I was in the hospital, they noticed that the blood sugars were high because I 
had too much glucose but they said it was temporary and it’s going to go down. 
But after a while, after one year, my doctor said I have diabetes. 
 
The reaction to the diabetes diagnosis was admittedly emotional for the participants in 
this group. As one said, “Sure I was upset. Who wants to have to watch what they eat all 
the time?” All participants in this group had accepted the diagnosis of diabetes and self-
identified as having type 2 diabetes. 
 In order to deal with diabetes, participants in this group integrated diabetes and 





routines, such as frequent follow-up care with both their cancer doctor and their diabetes 
doctor for long-term follow up and surveillance of both conditions. At the time of the 
interviews, each participant knew what their A1C should be and what theirs were. They 
were in the process of, or had already made, lifestyle changes to better manage their 
diabetes and cancer survivorship. They admitted to having some difficulty adhering to 
dietary (“especially around the holidays”) and exercise (“arthritis in the knees”) 
recommendations but also had strategies to improve health behaviors such as “not buying 
sugary foods,” exercising with a friend, joining a gym, or “getting a knee operation.” 
They were also planning for non-illness-related future events, such as retirement and 
vacationing with their families.  
 
Group Two: The Intermittent Complications Group 
 The second group were those who experienced acute post-allo-HCT 
complications, primarily GVHD and infections. All of these participants discussed 
receiving steroid treatments that, according to one participant, “shot their blood sugars 
through the roof.” They described the complexity of managing the “ups and downs” of 
their blood glucose levels. These participants were aware that their hyperglycemia was 
caused by the steroids they were on, and that it went away when they were taken off the 
medications. This awareness came from “nonspecific” or “vague” communication from 
the health care provider and from observing cues. The cues were, for example, as stated 
by this participant, “Just the labs being high and the adjusting of the medicine. We went 
through this process of changing medications and I saw how it affected the sugar levels.” 
This group identified with “having high blood sugars when on steroids,” and stated that 





 This group was able to deal with diabetes by “putting diabetes on the back 
burner” or trying not to think about diabetes when not on steroids. One participant stated 
that diabetes “did not affect [their] lives at all except for when on the steroids.” When on 
steroids, participants had to shift their focus back to illness self-care. At these times, 
participants went on-guard, becoming “more vigilant” and “checking [their blood glucose 
levels] more frequently” and “taking medication.”  
 It was apparent that there was some uncertainty in this group about their diabetes 
status. One participant was told he had “indications of diabetes” but noted he was never 
told he had diabetes. Other participants in this group also wondered if they “formally” 
had diabetes. This uncertain diabetes status led to worry about the future. Some feared 
“catching diabetes” while another said, “I mean what are blood sugars supposed to be, 
like what number should you start to worry?” Most of the time they were able to put 
diabetes out of their minds, but sometimes they wondered if they should be paying more 
attention to the condition. 
 
Group 3: The Ongoing Complications Group 
 This group had similar experiences with developing complications after the allo 
HCT as the second group with intermittent complications. Complications included 
infections in a few participants in this group, while all developed GVHD. Subsequently, 
they were treated with steroids and experienced variations in glucose levels. The 
difference with this group was that they were unable to have their steroids tapered or 
discontinued because the GVHD “wouldn’t let up.”  
 The ongoing work of managing GVHD and the side effects of treatment were 





the complexity of taking multiple medications: “It has been hard because I have to test 
four times a day and take insulin injections 3 times a day, and that is on top of about 20 
pills a day I take,” and: 
I have medications I have to take an hour before I can take any other medications, 
but I can’t be lying down for that, so I have to take that first for an hour, then I 
have to take my other medications, then I can eat something and then I can go to 
work, because I do work 40 hours a week.  
 
Other stories told of difficulties with symptoms, such as fatigue, neuropathy, and muscle 
wasting, and also confusion regarding what to attribute these symptoms to: cancer, 
diabetes, none of the above, all of the above, or other. 
 All participants in this group had ongoing GVHD for 2 or more years after allo 
HCT. They found out about having diabetes incrementally, through observing cues and 
through verbal input from the health care provider. The received message was that the 
diabetes would go away after the steroids were discontinued. During this time, they 
remained optimistic that treatments with steroids would be discontinued, and they would 
no longer have GVHD or the side effects that resulted from the treatments, namely 
diabetes. But as time progressed, and participants continued to have GVHD, they began 
to wonder just what exactly the health care providers meant by “temporary”. One 
participant was asked by the interviewer (JO), “Do you think you’ll always have to take 
medication to control your blood sugar?” and the participant replied,  “Yeah, they try to 
get me off of prednisone, but I always end up back on it, so I’d say it’s chronic.” Another 
participant said,  
It was easy enough to say “it [the hyperglycemia] is all because of the meds.” But 
wait a minute--we’ve been saying that for a long time already, and maybe it is just 
the meds, but it doesn’t look like I’m going to get off the meds any time soon.  
 





trajectory (“chronic temporary”) of the diabetes. 
 One participant described a sudden realization of having diabetes instead of the 
gradual realizations the others experienced. While on a high dose of steroids for GVHD, 
his daughter noted he was lethargic and took him to the emergency room. He stated, 
…..because when they tested me, I don’t remember what my numbers were, but 
they were way past…..Whatever number I had for blood sugar, I was supposed to 
be unconscious. But I wasn’t, so they told my daughter, “keep him awake, don’t 
let him go unconscious.” So it took maybe 8 hours, but they got my blood sugar 
under control and gave me instructions, and ever since then I’ve been pretty 
constant about looking for signs. 
 
This participant noted feeling “surprised” that the cause of the lethargy was 
hyperglycemia because up to this point the focus of his medical care had been exclusively 
on cancer-related issues and not on diabetes-related ones. 
 Once the participants self-realized the diabetes was not going away “any time 
soon,” they had a variety of psychological responses. They had emotional responses, such 
as being sad and indignant, as shown in the following quote: 
I guess, kind of emotionally sad, because I had been with my pregnancy, with my 
pregnancy with my daughter who is now 21, I had gestational diabetes, which 
runs really heavy in my family. So I had taken great measures to control my 
sugars and be really good so that I wouldn’t have it, because they say once you 
have gestational diabetes, you will get it later on in life. Then to get it because of 
the transplant, it was like all this time I have done all this good work and to get it 
because of all these medicines, it’s like, it’s not fair. 
 
They also responded by formulating an understanding of diabetes. They compared the 
two diseases, diabetes to cancer, and appraised diabetes as being not as bad as cancer—it 
was not life-threatening, and controllable. They also considered diabetes to be an 
inevitable side-effect of life-saving treatments and, therefore, there “was no other 
choice.” This is verbalized aptly by one participant: 





transplant because of the medications and the process. You know I have life, and I 
don’t have cancer, and I have other things like high blood pressure, diabetes, and 
neuropathy, things like that that are caused by the medications. But you know, we 
have ways to manage those things, so, it’s a tradeoff. 
 
 Diabetes was also compared to the ongoing work of managing GVHD. 
Participants were still focused on surviving cancer, as this participant illustrated: “You 
have to learn to treat the side effects, not fight them. And diabetes is a side effect. You 
are fighting the cancer, you got to focus on fighting the cancer, not fighting the side 
effects.” This work of surviving was appraised as more complex and burdensome than 
diabetes-related work, as shown in the following statements: “the diabetes part of it is a 
nonexistent piece of it because I am so restricted because of my transplant and GVH 
disease,” and “with all the medications I am on, I said the diabetes is the least of it.” After 
the life-threatening experience of having cancer and allo HCT treatments, diabetes may 
indeed seem benign. 
 In addition to comparing diabetes to cancer and related complications, 
participants contrasted their diabetes with other types of diabetes they knew about. This 
group identified with having “steroid-induced” or “chemically-induced” or “not real” 
diabetes as opposed to the stigma-laden diabetes with which they were more familiar. 
They understood that there was no self-blame associated with this type of diabetes. It was 
a side effect of life-saving cancer treatments and not their “fault.”  
  When asked how they managed diabetes, participants all expressed similar 
resolute attitudes. Many quotations echoed this same outlook: “You have to keep on 
moving forward, and you know this is just one more thing that we have to deal with and 
keep moving forward,” and “it’s just something I am going to have to deal with,” and 





after cancer.   
 Absent in this group was talk about planning and strategizing future diabetes self-
management. Instead, participants were focused on meeting day-to-day demands of 
illness and life. They also found it hard to find support from HCP who understood “their 
type” of diabetes. One participant said she had to prove to the doctors the enormity of the 
work of self-management before they finally understood that she did not have “resistance 
to managing diabetes like other people with diabetes do,” she just needed to “figure out 
how to fit it all in.” 
 Two participants who attended diabetes self-management education also noted 
that the program was not tailored to their “kind of…. different” needs as shown below:  
I know that as I sat there in the classes, they were talking about how you have to 
make these changes, and it’s up to you, and kind of emphasizing that, which 
under a normal diabetes conditions, yeah, it is totally up to you, and you have all 
the control. But in this case, I don’t have all the control. So there is a fine line 
there. 
 
This quote shows how the cause of diabetes, as related to the medications, made this 
participant wonder if the diabetes management strategies recommended for their type of 
diabetes were the same as people with the other types of diabetes.  
 Participants noted they were not always able to perform diabetes self-management 
behaviors consistently. Behaviors mostly discussed in the narratives were exercise, diet, 
and checking blood glucose levels. Some noted physical reasons for not being able to 
adhere to recommendations. Difficulty to perform exercise was said to be due to residual 
weakness, fatigue, and neuropathy. Some participants had cancer-related dietary 
restrictions that interfered with recommendations, while others were able to incorporate 





am allowed to eat or that I am not allowed to eat is, basically if you were a diabetic, you 
would be that way anyway.” Quotes illustrating difficulty with adherence to medications 
due to the number of prescriptions were presented earlier. Another participant admitted 
he was unsure what each of his 42 medications were for, and did not know if he was on 
any diabetes medications. After reviewing with the researcher (JO) the Excel medication 
sheet he created to track his medications, we determined he was indeed on a scheduled 
diabetes medicine. 
 At times, diabetes self-management behaviors were not performed, not due to 
competing work or physical inability, but because they conflicted with the participants’ 
goals and priorities. This was predominantly seen in quotes related to food. Participants 
talked about how they were going to “eat birthday cake,” “go out to dinner and not think 
about what they were eating all the time,” because, as this participant said, “I survived 
cancer, I survived stem cell transplant twice. Screw it! I am going to live my life and eat 
what I want and drink and whatever.”  Participants admitted to not letting diabetes “stand 
in the way” of doing what they wanted. Here is an example, “I can indulge a little bit 
because I wasn’t given a second chance at life to forgo all the things I love, but I have to 
be reasonable about it.” Self-monitoring was an area that participants felt they should be 
doing more often, and, as one participant noted, 
I am not good at testing my blood sugar. I may have really high blood sugar right 
now and not even know it. But I am not going to let that affect what I enjoy in 
life, and eating and exercising and whatever I can do.  
 
This demonstrated how participants prioritized the need “to live life differently, enjoy life 
more,” “take full advantage of life,” and “make the most of it.” Sometimes present-








 The experience of developing new-onset diabetes after allo HCT resulted in the 
identification of prestages prior to the awareness of developing diabetes. This was the 
context for which the experience of developing diabetes occurred. The theory of dealing 
with new-onset diabetes as a long-term effect of allo HCT identified stages of the 
developing diabetes experience as 1) finding out about diabetes, 2) formulating an 
understanding of diabetes in relation to cancer, 3) formulating a diabetes identity, and 4) 
dealing with diabetes after allo HCT. Groups of participants moved through these stages 
differently based on their post-allo-HCT recovery status. Table 4.2 illustrates the 
differences of patterns of movements that emerged by group. Group 1 had minimal or no 
complications post-allo-HCT, group 2 had intermittent complications, and group 3 had 
ongoing complications. The presence or absence of complications resulted in differences 
between how participants 1) identified with diabetes and 2) prioritized diabetes. These 
differences resulted in groups having very different response to diabetes and how they 
performed diabetes self-management behaviors.  
 
Discussion and Implications by Group 
 
 Despite lack of supportive evidence, recommendations for new-onset diabetes that 
occurs after allo HCT are to manage it similarly to type 2 diabetes (Griffith et al., 2010). 
Central to these recommendations is glycemic control through medical and self-
management of diabetes. The latter, self-management, accounts for the majority of the 





self-manage diabetes, they must integrate self-management into their daily lives. 
Integration is a psychosocial adaptive response to diabetes that has been explained in 
several theoretical frameworks (Audulv et al., 2012; Hörnsten et al., 2011; Whittemore & 
Dixon, 2008). The results of this emergent theory provide a theoretical description of the 
process of change that occurs in the substantive area of new-onset diabetes after allo HCT 
in middle age and older adults. By comparing stages and processes of change, in 
conjunction with factors that influence these processes, HCPs can discern what 
interventions are needed to promote diabetes adaptation and prevent maladaptation.   
 
Discussion and Implications for the No or Minimal Complications Group 
 Group 1 had an adaptive response to developing new-onset diabetes after allo 
HCT. To review, group 1 recovered with no or minimal complications. When they 
continued to have diabetes after all possible transient diabetogenic causes were removed 
(i.e., infection and steroids), it was clear that a permanent, internal physiological deficit 
was causing the diabetes. Subsequently, this group developed a clear understanding of 
their diabetes status and a clear identity as people with diabetes. They were able to 
successfully adapt to diabetes by integrating diabetes and cancer self-management. This 
was similar to the experience of individuals without a cancer diagnosis who adapted to a 
new-onset type 2 diabetes diagnosis, as presented by Hörnsten (2011) in the background 
section.  
 Knowledge from this study is useful to practice as it indicates that management 
strategies recommended for people with type 2 diabetes are appropriate for this group. 
Diabetes self-management education programs intended to increase the knowledge and 





difficulty concentrating during the acute recovery phase, education should include a 
caregiver and be available in written format for all individuals who develop diabetes after 
allo HCT. Of particular import to this group’s positive outcome was the relationship 
between clear and timely diagnosis of diabetes and adaptation. HCPs are therefore 
encouraged to communicate diagnosis of type 2 diabetes as early as possible. 
 
Discussion and Implications for the Intermittent Complications Groups 
 Group 2 went through the stages of the theory, but had a different pattern of 
movement due to the acute complications they developed. These complications 
necessitated treatment with steroids. This group was aware that steroids were the external 
reason for the diabetes because when they were not taking steroids, they did not have 
high blood glucose levels. Because of this, they never formulated an identity as people 
with diabetes or integrated diabetes self-management into their lives.  
 It can be argued that how this group responded to having diabetes was successful. 
They became vigilant during acute hyperglycemia and put it on the back burner in 
between. What was confusing for participants however, was that they compared what 
they knew about the more familiar types of diabetes to their own less-known type of 
diabetes. They were left with questions regarding the status of their current and future 
health and quality of life.   
 Implications for practice therefore should include education directed towards 
these concerns. This education should include information regarding their current 
temporary condition, the adverse effects of acute hyperglycemia, and methods to self-
manage their steroid-induced condition. Resources for management of steroid-induced 





Armstrong, & LoBiondo-Wood, 2014) and for outpatient management (Clore & Thurby-
Hay, 2009; Kwon & Hermayer, 2013). Regarding future status, individuals with steroid-
induced diabetes should be informed that they are at increased risk for developing overt 
or frank diabetes (Clore & Thurby-Hay, 2009; Kwon & Hermayer, 2013). Therefore 
education regarding early detection and prevention of diabetes is vital for this group. Of 
note, the lack of diagnostic clarity between the terms transient hyperglycemia and 
permanent diabetes created some confusion for this group. Future policy implications 
would therefore also including coming to a clinical consensus regarding the differences 
between these two conditions.  
 
Discussion and Implications for the Ongoing Complications Group 
 This group is the most complex, heterogeneous, and vulnerable group and 
therefore a substantial amount of attention is devoted to this cohort. Group 3 experienced 
ongoing complications after receiving allo HCT, namely chronic GVHD, and were 
receiving ongoing treatment with steroids. These participants were saddled with ongoing 
and arduous illness-related work. Glycemic control was part of this work. Corbin and 
Strauss (1988) noted that individuals with limited resources to conduct competing lines of 
work will establish priorities to determine where limited resources will be allocated. In 
this study, individuals prioritized work that was present-focused, such as taking daily 
medications, going to work, and enjoying the moment. Work that was future-focused, 
such as eating healthy and thinking about self-identity, were often of lesser importance.  
They “just dealt with” this work reactively instead of proactively. This intense focus on 
the present has been described as enduring to survive by Morse and Carter (1996).  





et al., 2013) and identify areas where HCPs can support and assist individuals, so present-
focused work can be decreased and they may be able to shift to future-related work such 
as wellness promotion and disease prevention. Less stringent glycemic targets (as 
discussed by Inzucchi et al. (2015) may also be considered. Consistent, ongoing support 
is clearly needed for this group: Care management would be well suited to meet this 
need. 
 In addition to the amount of work, participants in this group had barriers to 
moving through the stages of the theory because of the uncertain timeline of the 
condition. Like the other two groups, this group initially understood their diabetes to be a 
side-effect of the steroids. As time progressed, they gradually understood that the GVHD 
was “not going away anytime soon” and that steroids and the side effects of steroids, 
would be permanent. This gradual realization did not occur until 2-4 years after allo HCT 
in this group. This contrasted with the relatively rapid realization of the group with no or 
minimal complications, at 6-9 months. Prior to this realization, diabetes was a side-effect 
of treatments that would hopefully go away. This initial perception of diabetes as 
transient hindered movement through the stages of finding out about diabetes and 
formulating a diabetes identity.  
 Another variation in this group’s pattern of moving through the theory occurred 
because of the lack of diagnostic labeling. Without a clear understanding of their 
condition, these participants attempted to formulate their own understanding. They did 
this by comparing diabetes to cancer. This led to diabetes being perceived as “not as bad 
as cancer.” And while positive reframing of an illness has had both positive (Paterson, 





led participants to underprioritize diabetes. This prioritization of cancer over diabetes has 
been found in other studies as well (Hershey, Tipton, Given, & Davis, 2012; Irizarry et 
al., 2013). They also formulated an understanding of their diabetes as an “other type” of 
diabetes, and distanced themselves from stigma-laden type 2 diabetes. Distancing self 
from illness has been shown to be a coping mechanism in some chronic illnesses 
(Paterson, 2001), while it has undermined self-management agency in others (Broom & 
Whittaker, 2004). In this study it led to participants feeling misunderstood and 
unsupported by HCPs that did not understand the diabetes with which they had identified.  
 Implications for practice would therefore be to assess individuals’ beliefs about 
diabetes identity, timeline, cause, and priority, and correct any inaccuracies. To head off 
inaccurate beliefs from forming in the first place, clear and early communication 
regarding diabetes status (i.e. type, timeline, cause, consequence) is indicated to facilitate 
clear understanding, timely identification, and adaptation to diabetes.  
 
Establishing Diabetes Status 
 This is easier said than done. In the case of GVHD, it is not always possible to 
discontinue steroids in order to delineate whether blood glucoses levels are elevated 
because of steroids, or due to physiological changes that have occurred in the body 
during the allo HCT process. The American Diabetes Association (ADA) categorizes 
diabetes based on the underlying pathology. In the case of new-onset diabetes, it is not 
always possible to understand the cause, and therefore a definitive diagnosis has 
remained elusive. The ADA (2004) has stated “for clinician and patient, it is less 
important to label the particular type of diabetes than it is to understand the pathogenesis 





indicated that failure to apply a diagnostic label hindered participants’ ability to appraise 
seriousness of diabetes, identify as a person with diabetes, and subsequently integrate 
diabetes self-management into their everyday lives.  
 What is to be done? We have discussed the difficulty with understanding the 
underlying cause and the timeline of diabetes in this group because of reliance on 
steroids. Is there a point in time when HCPs could diagnose patients with a permanent 
type of diabetes? Unfortunately, there are few data regarding the long-term risk of the 
development of overt diabetes in the GC treated patients. Therefore, implications for 
research are to dedicate resources towards better understanding the natural progression of 
new-onset diabetes after allo HCT. Having a medical construction (definition and 
treatment guidelines) of this condition would be useful to inform patient-provider 
communication regarding diabetes status. This would allow individuals with the 
condition to identify as person with diabetes early and to formulate accurate 
understanding of their diabetes status. Having a medical construction would also enable 
researchers to identify individuals with new-onset diabetes after allo HCT through 
administrative data coding to inform the development of evidence-based practice 
interventions aimed at maximizing patient outcomes. 
 Recently, the ADA and Juvenile Diabetes Research Foundation held a symposium 
entitled Differentiation of Diabetes by Pathophysiology, Natural History and Prognosis 
Research (ADA, 2015). The aims of this workgroup were to “develop a clinically-useful 
and broadly-applicable staging system to guide patient-centered management of type 1 
and type 2 diabetes” (para. 2). This may prove to be a model that could be used to 







 The landscape of allo HCT recipients is changing to include middle age and older 
adults. Older adult recipients of allo HCT are at increased risk for developing diabetes as 
a long-term effect. To improve outcomes for this growing cohort, a thorough 
understanding of the biomedical and psychosocial aspects of the condition is required. 
The results of this study provide a theoretical rendering of the psychosocial process and 
the stages within, that occurs when older adult recipients of allo HCT develop new-onset 
diabetes. 
 Important to all psychosocial processes of change from illness to health is 
knowing the influencing factors so interventions can be developed to guide individuals 
towards adaptation. In this study, the main influencing factor was the presence of post-
allo-HCT complications, namely GVHD, and steroid use. This modified patterns of 
movement through the change process. Three groupings of patterns were delineated: 1) 
no or minimal complications, 2) intermittent complications, and 3) ongoing 
complications. Complications were primarily GVHD necessitating steroid therapy. 
Specific implications are provided for each of these trajectories. Participants with few or 
acute complications were able to identify with diabetes, accurately prioritize diabetes, 
and perform self-management behaviors. Participants with ongoing complications had 
increased illness-related work and an unclear understanding of their diabetes. Managing 
GVHD and the side effects of treatment meant individuals did not have the resources to 
conduct the biographical work that was necessary to successful transition from illness to 
health within illness. In diabetes that occurred after allo HCT, it was evident that GVHD 





a barrier to identifying with diabetes and prioritizing secondary prevention of diabetes 
over present-focused survival needs.  
  There are multiple implications of these findings to both practice and research. 
First, HCPs should assess and support ongoing cancer-treatment-related work. Second, 
frequent communication about current and future diabetes status is recommended, in 
particular with regards to the possible causes, the timeline, and consequences of diabetes. 
Third, a diagnostic label should be applied to individuals as early as possible in the 
course of diabetes. Fourth, diabetes beliefs and life priorities should be assessed and 
considered in plans of care. Fifth, education on the importance of glycemic control in 
diabetes of all types should be emphasized. Sixth, tailor self-management education by 
locating the individual within the stages of the theory. Finally, to facilitate all these 
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Figure 4.1 Actual presentation of hyperglycemia/diabetes  
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DISCUSSION AND CONCLUSIONS 
 
 
This chapter discusses specific implications for practice and directions for future 
research based on study results, as well as reflections on next steps specific to my own 
trajectory as a nurse scientist. Implications for policy are also discussed. 
 
Impetus for My Research Question 
 
The impetus for this study was my own experience as a diabetes educator at an 
oncology hospital. Prior to working in the oncology setting, I worked in a rural diabetes 
clinic. My role in both settings was to provide diabetes education. I had on-the-job 
training and formal coursework during my training as a diabetes educator. This training 
was developed nationally and based on a compilation of rigorous research on individuals 
with type 1, type 2, and gestational diabetes: I was taught how to provide education for 
the normal distribution of the population with diabetes.  
When I began work at the oncology hospital, I tried to impart patient education 
specific to diabetes to my new patients. These patients, however, had very different 
questions, such as, Will controlling diabetes improve my cancer survival chances?, Do I 
really have diabetes?, Is my kind of diabetes permanent, and why wasn’t I told that I 
would get diabetes before the treatments started? I quickly realized people who 





To improve my understanding of patients with diabetes after allo HCT, I 
conducted a literature review to synthesize knowledge regarding the acute biophysical 
effects of hyperglycemia on allo HCT outcomes (Olausson et al., 2014).  I then searched 
the literature for what was known about the long-term psychosocial effects of diabetes. 
Since I had just met with a nurse researcher who introduced me to David Eton’s work on 
measuring burden of treatment (Eton et al., 2013; Eton et al., 2012), one of my early 
dissertation research ideas was to measure burden of treatment in my cohort of interest. 
Burden, therefore, was included in the list of search terms used to explore psychosocial 
effects of new-onset diabetes after allo HCT. Multiple databases were searched, but I was 
unable to find any information on the topic. Even the article entitled “The burden of new-
onset diabetes mellitus after transplantation” (Moore, Ravindran, & Baboolal, 2006), 
reported only clinical outcomes and not the psychosocial burdens  that I assumed would 
be present in people who had just gone through a presumably difficult experience with 
cancer. 
Finding this gap in knowledge directed my research question and methodology: 
since so little was known, I would use qualitative inquiry. In addition, I was influenced 
by my professors and mentors. Reading assignments from Dr. Clark’s and Dr. Morse’s 
courses introduced me to the works of Todres et al. (2009) and Morse (2010, 2012) 
regarding the critical role the qualitative nurse researcher has in preserving humane 
treatment in the health care system. This aligned with my own feminist and social rights 
agenda I had cultivated through my own experiences. I felt the need to stand up for these 





In the absence of any studies on the psychosocial experiences of middle age and 
older adults with new-onset diabetes after allo HCT, I reviewed qualitative research 
conducted on individuals who developed chronic illness, including diabetes and cancer. 
These studies in chronic illness corresponded with the earlier research findings (Corbin & 
Straus, 1988) that showed that adaptation, or positive responses to changes in health, was 
the result of going through a process of restructuring identity, coming to terms with the 
new self, and making new meanings. In research specific to diabetes, the adaptive process 
was found to be made up of stages which included becoming aware of the diagnosis, 
searching for meaning within the diagnosis, accepting the diagnosis and coming to terms, 
and integrating diabetes and self-management into everyday life (Hörnsten et al., 2011). 
Cancer survivors found positive outcomes through meaning making (Lee, 2008). This 
process of meaning making could only begin after the threat of cancer was diminished 
and individuals could reflect and take stock of their experience (Park et al., 2008).  
My goal for this research study was to identify and interview people who had 
diabetes as a long-term complication of cancer treatments. Inclusion criteria were that the 
participant had experienced having diabetes for at least 1 year after transplantation. I 
identified participants by using International Classification of Disease (ICD)-9 codes for 
diabetes and by checking their last three medical dictations to ensure diabetes was 
mentioned as a comorbid condition. However, when I talked to some of the eligible 
participants, they stated they did not have diabetes; they only had high blood sugars when 
they were taking steroids. This was group 2, the group with intermittent complications. 
Having participants from this group elucidated differences between how these 





The clinical differences between types of diabetes survivors of allo HCT 
experienced forced me to reconsider my own role in the development of the emergent 
theory. While both constructivist grounded theory and Glaserian grounded theory use 
constant comparison to ensure the resulting theory is representative of the participants’ 
reality, I realized that it was only because of my knowledge and experience with diabetes 
and cancer that I was able to identify the variations in patterns of movement through the 
stages of the theory. I was familiar with the relationship between types of diabetes, 
GVHD, and steroids and therefore was able to interpret the self-identification dilemma 
expressed in these two comments, “it is like this week I have diabetes and the next week I 
don’t,” or “maybe it [hyperglycemia] is the meds, but we have been saying that for a long 
time, it doesn’t look like it is going away any time soon.” A different researcher, lacking 
the same insight, may have missed this data or had fewer interpretive resources.  I came 
to the conclusion that my knowledge and experience with this type of diabetes were a 
variable in the development of the final theory—I interpreted and co-created the results 
based on my own knowledge and experiences.  
 
Implications for Practice  
 
The primary objective of this study was to discover the basic psychosocial process 
middle age and older adults experienced when developing new-onset diabetes after 
receiving allo HCT for treatment of hematological cancer. The participants also discussed 
their experiences prior to developing diabetes, their experiences with cancer and cancer 
treatments. These narratives provided the data utilized for developing the prestages of the 






Implications: During the Acute Allo HCT Phase 
The four prestages of the theory included 1) facing cancer/existential plight, 2) 
undergoing allo HCT treatment/diabetes as a side effect of cancer treatment, 3) being 
grateful for having survived the immediate existential threat, and 4) continuing allo HCT 
recovery work. These prestages coincided with the acute phase of allo HCT. During this 
acute phase, recipients are at high risk for adverse effects of treatment. The importance of 
glycemic control during this period on allo HCT outcomes was explored by Olausson, 
Hammer, and Brady (2015). During the inpatient phase, glycemic management of 
hyperglycemia is the responsibility of the HCPs. When the allo HCT recipients transition 
to home, the responsibility for glycemic control shifts to the recipient and their caregiver. 
They must learn how to manage diabetes and recovery from cancer treatments 
simultaneously. The amount of discharge education can be overwhelming (Cooke, Grant, 
& Gemmill, 2012). Even when diabetes education was provided during hospitalization, 
patients still had many questions regarding diabetes and diabetes management after HCT 
(Cooke, Grant, & Gemmill, 2012). Participants in the current study also had difficulty 
recalling events experienced during their inpatient stay. Therefore, implications for 
patient education would be to minimize the content of diabetes discharge education to 
only include key information necessary for patient safety during the transition to home. 
These survival skills have been developed by the American Association of Diabetes 
Educators (American Association of Diabetes Educators, 2012). Patients who undergo 
allo HCT must often designate a caregiver who will support them during the recovery 
period. Providing written and verbal survival skill education to the patient and their 





therapy during the recovery period, additional content necessary for this group would 
include information on the outpatient management of steroid-induced diabetes (Clore & 
Thurby-Hay, 2009; Kwon & Hermayer, 2013).  
 
Implications: During the Transition and Recovery Phase 
After the immediate threat of cancer diminished, participants took stock in their 
surroundings and began to make sense of their experience. Participants became aware 
that their blood glucose levels remained elevated during the finding out about diabetes 
stage. Subsequent stages followed, including formulating an understanding of diabetes in 
relation to cancer, formulating a diabetes identity, and dealing with diabetes post-allo-
HCT. This study demonstrated how there were three variant patterns of movement 
through the 4 stages primarily due to 1) the degree of treatment-related work (primarily 
GVHD and treatment with steroids) and 2) the perception of diabetes status. These 
differences resulted in groups having very different responses to diabetes and diabetes 
self-management behaviors. While members of the group with no or few complications 
had adaptive responses that included integrating diabetes and cancer self-management, 
and the group with intermittent complications responded by being vigilant when needed, 
the group with complications had had many factors that hindered their ability to progress 
through the stages of the theory and positively deal with diabetes. They dealt with 
diabetes by taking it day by day.  
How can HCPs use this information to improve patient outcomes? First, clearly 
match the allo HCT recipient within a group based on their steroid use and glucose 
patterns. If the individual is experiencing persistent and ongoing elevations in blood 





would be considered in the first group, the minimal complications group. If a potential 
cause of hyperglycemia is present, then the individual should be considered either group 
2 or group 3. The difference being that group 2 experiences episodic hyperglycemia in 
response to episodic pathologies (i.e., infection and acute flares of GVHD requiring 
intermittent treatment with steroids). Group 3 would have persistent and ongoing 
hyperglycemia to match their persistent and ongoing complications and treatments for the 
complications. These differences in groups were illustrated in Chapter 4 (Table 4.1). Next 
would be to assess for the two factors that had the most influence on movement, the 
degree of treatment-related work and the understanding of diabetes status. 
 
Assessing the Effect of Cancer Treatments 
The group with the ongoing complications described several long-term effects of 
their treatment with allo HCT. In addition to persisting physical symptoms of fatigue and 
neuropathy, participants in this group described the effects of self-managing their 
recovery from allo HCT. Participants were saddled with new responsibilities, including 
taking medication, monitoring, assessing symptoms, frequent follow-up visits, and 
performing healthy behaviors. The efforts required to manage one’s own altered health 
have been referred to as illness-related work (Corbin & Straus, 1988; Klimmek & 
Wenzel, 2012). In this study, participants described efforts needed to self-manage effects 
of cancer treatments, including diabetes management, and therefore, I referred to this 
work as treatment-related work.  
The tremendous amount of treatment-related work participants in the ongoing 
complications group experienced precluded concentrated efforts directed towards 





term effect of allo HCT (finding out about diabetes, formulating an understanding of 
diabetes, formulating a diabetes identity, and dealing with diabetes after allo HCT). 
Corbin and Strauss (1988) identified the process of developing chronic illness as having 
similar stages, namely developing an illness identity, coming to terms with the new 
normal, and integrating illness into everyday life. Corbin and Strauss (1988) termed this 
work as biographical work, and found it to be an integral part of adaptation to illness. In 
this study, a high degree of treatment-related work hindered participants’ biographical 
work. Others studies have noted that when a person is engrossed in present-oriented 
illness-related work, or focused on illness (Paterson, 2001), or enduring to survive 
(Morse & Carter, 1996), they are unable to simultaneously focus on future-oriented 
biographical work of finding health within illness.  
The negative relationship between treatment-related work and adapting and 
integrating diabetes into one’s life was the most profound and clinically relevant finding 
of this study. It is therefore imperative to assess what type of health-related work a person 
is conducting in order to guide health care interventions. Although there are several 
methods for assessing patient-reported health and health-related quality of life for 
individuals after allo HCT (Pidala, Anasetti, & Jim, 2009), a measurement tool to assess 
the degree of cancer treatment-related work has not been developed. Until such a tool is 
available, health care providers (HCPs) can simply ask the individual how they are doing 
and listen to their response. The following quotes are some examples of participants 
focused on present-oriented treatment-related work: 
When I was talking to my health care provider over the phone, I was like, just 
help me figure out a way to fit this into my day. I have medications I have to take 
an hour before I can take any other medications, but I can’t be laying down for 





medications, then I can eat something and then I can go to work, because I do 
work 40 hours a week.   
 
So there is eye medication as well as testing as well as some of the liquids and I 
have got to take extra calcium and potassium and you know, just aside from all 
the other the prescriptions, so I don’t even try to figure out what day it is. 
 
These participants were grappling with how to manage treatment-related work. In 
contrast, participants focused on the biographical work of developing new-onset diabetes 
(finding out, formulating an understanding, and formulating a diabetes identity) asked 
why and for how long they need to manage diabetes and questioned what type of diabetes 
they had.  Supportive interventions need to be directed towards the type of health care-
related work individuals are focused on.   
 
Assessing Diabetes Perceptions 
Individuals who are conducting biographical work of developing new-onset 
diabetes can be assessed for perceptions of diabetes. The components of diabetes 
perception that were relevant to participants in this study were cause, timeline, identity, 
consequences, and control. Perceptions of cause and timeline were important to the first 
two stages of the theory, finding out about diabetes and formulating an understanding of 
diabetes in relation to cancer. The perceptions of cause and timeline then influenced 
perceptions regarding the severity, or consequences, and controllability, and the next 
stage, formulating a diabetes identity. Assessing these perceptions for accuracy can help 
HCPs to direct interventions aimed at facilitating adaptation to diabetes.  
Table 5.1 illustrates diabetes perceptions of participants in the current study by 
group. It also highlights diabetes perceptions that were inaccurate or not in alignment 





through the stages of theory of developing new-onset diabetes because of clear and 
accurate perceptions regarding diabetes. They had a timely diagnosis of diabetes, had a 
clear understanding of their illness, and were able to self-identify as cancer survivors with 
type 2 diabetes. Diabetes education programs recommended for the general population 
with type 2 diabetes (American Association of Diabetes Educators, 2014) or chronic 
disease self-management programs for people with multiple chronic conditions such as 
diabetes and cancer (Lorig et al., 1999) would be ideally suited for this group.  
As discussed in Chapter 4, Group 2, the group with intermittent complications 
requiring treatment with steroids also progressed through the stages of the theory with a 
clear understanding of the cause and timeline of their diabetes, but they were uncertain of 
the consequences. They asked questions regarding when and if their diabetes could cause 
adverse effects. Implications for practice for this group have been described in Chapter 4 
and have been supported by research surrounding steroid-induced hyperglycemia in the 
allo HCT and general populations.  
The group with the most inaccurate perceptions of their diabetes was the group 
with ongoing complications and steroid use (group 3): In fact, they had some degree of 
inaccuracy in all of the 5 identified components of illness perception. There were two 
main reasons found for these discrepancies between diabetes perceptions and scientific 
knowledge. The first was the continued work of treatment as discussed in the previous 
section. The second was the uncertainty participants felt regarding the cause and timeline 
of their diabetes. Because steroids were perceived as the cause, group 3 believed that 
their diabetes might go away when the medications were discontinued. This study found 





respond positively to new-onset diabetes. Moreover, it has been found that a person who 
believes their diabetes is temporary may have little motivation to change lifestyle habits 
to maintain good glycemic control (McSharry, Moss-Morris, & Kendrick, 2011). 
Therefore, it is important to improve our understanding of the prevalence and predictors 
of chronic GVHD to guide patient-provider communication regarding temporary versus 
ongoing diabetes.  
Until we have a better understanding of who is at risk for developing new-onset 
diabetes, all individuals considering allo HCT should have some pretransplantation 
education regarding the potential for developing transient and persistent diabetes. During 
the pretransplantation period, the allo HCT candidate and their caregiver are provided 
with a large quantity of educational material regarding the HCT process and anticipated 
recovery trajectory (see Appelbaum & Thomas, 2009). The amount of content is 
potentially overwhelming to the candidate and their caregiver. This can cause clinicians 
to deliberate over what content to include when preparing a person for allo HCT. Is risk 
of developing new-onset diabetes essential information to be discussed during the 
emotional, stress-filled pretransplantation phase?  
Making a paternalistic decision not to inform patients may seem benevolent at the 
time, but it may not be the correct one. Codes of ethics for health care providers state that 
autonomy is a fundamental bioethical principle that should be upheld when making 
decisions in health care (Fowler, 2015; Beauchamp & Childress, 2013). Full disclosure to 
a patient about risks and benefits of treatment allows individuals to be informed and 
active members of the shared decision-making process. In addition to empowering 





been found to lower distress and improve coping, self-management adherence, recovery, 
and quality of life (Knobf, 2013). An implication for practice, is therefore, to inform 
individuals prior to transplantation about the possibility of developing new-onset diabetes 
after allo HCT in order to better prepare them for long-term recovery from allo HCT. 
These assessments will allow HCPs to determine if an individual is able to 
independently self-manage their health condition, or if they need some support. Those 
needing support may benefit from care management. Care management is a set of 
activities designed to assist patients and their caregivers in managing health conditions 
and related psychosocial problems more effectively (Berry-Millett & Bodenheimer, 
2009). The goals of care management are to improve patients’ functional health status, 
enhance coordination of care, eliminate duplication of services, and reduce the need for 
expensive medical services. It is ideally suited for those with multiple chronic conditions 
such as cancer and diabetes who experience issues with having multiple HCPs such as 
polypharmacy, duplication of clinical procedures, frequent and unnecessary 
hospitalizations, delays in access to services, and inappropriate interventions (Extermann 
& Hurria, 2007; Gallo, Gentile, Arvat, Bertetto, & Clemente, 2016). 
A specific type of care management program is care transition programs. These 
programs have been shown to effectively and efficiently help hospitalized patients with 
complex chronic conditions transfer from one level of care to another, leading to a 
reduction in hospital readmissions (Naylor, Aiken, Kurtzman, Olds, & Hirschman, 2011). 
Typically, care transition programs utilize specially trained coaches, who typically have 
backgrounds in nursing or social work, to educate patients about medication management 





continuity and communication with their HCPs. The coaches, who visit patients in the 
hospital and make home visits and phone calls for 28 days after discharge, also provide 
guidance that helps patients recognize symptoms that indicate their condition is 
worsening. These programs are well matched to the multiple transitional needs 
experienced by allo HCT recipients who have complex discharge care plans and high 
documented readmission rates from 38-51% due to their compromised immune systems 
and high risk for postdischarge complications (Grant, Cooke, Bhatia, & Forman, 2005; 
Rauenzahn et al., 2014). Continuity of care has also been found to increase quality of life 
in older adults with chronic illness (Chen, Tu, & Chen, 2016) and is recommended for 
this complex population of older adults with comorbid diabetes and cancer survivorship. 
 
Implications for Research 
 
It was important for participants in every group to identify with some type of 
diabetes in order to socially construct their illness and integrate it into their lives. 
Participants without a diagnostic label could not identify with people with more common 
types of diabetes, such as type 2 diabetes. Consequently, they felt misunderstood by their 
doctors who did not understand their type of diabetes. In addition, they felt alienated from 
support groups targeted to people with type 2 diabetes.  Chapter 4 addressed the 
difficulties surrounding identifying both the timeline and type of diabetes experienced by 
people with ongoing GVHD and steroid use. Diabetes in this case may be new-onset 
treatment-related diabetes or type 2 diabetes.  
Recommendations for research include the need to explore the natural progression 
of diabetes that occurs after allo HCT. This information can be used to medically 





new-onset diabetes after allo HCT would help to identify people with this condition for 
research studies. Subsequently, results from this research would inform scientific 
knowledge about this group and inform evidence-based treatment guidelines. 
Assessment tools for measuring the two factors most responsible for variation in 
the patterns of movement throughout the theory should also be developed. Burden of 
treatment is a construct that is currently being developed and refers to the workload of 
health care and its impact on patient functioning and well-being. A tool to measure these 
psychometric properties of burden of treatment in complex patients is also being 
validated by Eton and colleagues (Eton et al., 2013; Eton et al., 2012).   
An existing tool validated to assess diabetes perceptions in the general population 
is the revised Illness Perception Questionnaire (Moss-Morris et al., 2002).  This tool is 
derived from the Common Sense Model (Leventhal, Brissette, & Leventhal, 2003) and 
measures 5 major cognitive components of illness perceptions: identity, cause, timeline, 
consequences, and cure-control. The identity component addresses the label of the illness 
and the symptoms the patient views as being part of the disease. Cause relates to personal 
ideas about the etiology of diabetes. Timeline is regarding how long the patient believes 
the illness will last and can be categorized into acute, chronic or episodic. Consequences 
includes the expected effects and outcome of the illness; and cure/control, how one 
recovers from, or controls, the illness. These 5 components of illness perception have 
been linked with a range of psychological outcomes, including coping, functional 
adaptation, adherence to medical recommendations (as described by(Hagger & Orbell, 





(McSharry et al., 2011). This tool should be validated to assess diabetes perceptions in 
middle age and older adults with new-onset diabetes after allo HCT.  
An additional assessment tool with face validity is motivational interviewing 
(Rollnick, Heather, & Bell, 1992). A component of motivational interviewing includes 
assessing an individual’s perceptions regarding confidence to perform recommended 
behavioral changes versus their perception of how important the change is to them. 
Knowing confidence and prioritization of older adult allo HCT recipients towards self-
managing diabetes would provide insight towards health care interventions. Perceived 
lack of confidence with performing diabetes self-management skills could indicate 
patients need assistance with learning and/or carrying out skills, while perceived low 
importance of diabetes self-management tasks may indicate education should be directed 
at the rationale for performing the tasks. Research aimed at establishing significant 
associations between these variables would provide HCPs with another tool to use to 
understand perceptions of individuals in this cohort and guide subsequent interventions.  
After these assessment tools are validated in this population, it will be possible to 
establish baseline metrics for health care outcomes and measure the effects of supportive 
health care interventions.  
 
Implications for Health Professions Education 
 
Health professional education based on a single-disease framework fails to 
consider the context in which diseases occur. It is estimated that two thirds of Medicare 
beneficiaries 65 years or older have two or more chronic conditions (Centers for 
Medicare and Medicaid Services, 2014; Lochner, Goodman, Posner, & Parekh, 2013). 





multiple chronic conditions (MCCs). The Chronic Care Model (CCM) is a framework for 
management of chronic conditions that is increasingly being included in HCP education. 
The CCM posits that management of complex MCCs requires informed and engaged 
patients, interacting with a prepared, proactive, interdisciplinary teams, collaborating 
across many disciplines in order to maximize patient outcomes. (Bodenheimer, Wagner, 
& Grumbach, 2002; Victoria J. Barr & Sandy, 2003). A core competency included in 
health professional education includes working in interdisciplinary teams (IOM, 2003). 
Advanced practice registered nurses are well positioned to lead and contribute to 
interdisciplinary teams (American Association of Colleges of Nursing, 2011) focused on 
designing, implementing, and evaluating coordinated, patient-centered care for people 
with new-onset diabetes after allo HCT.  
With regards to education specific to managing diabetes and comorbid cancer, the 
Glycemic Control for People with Cancer Taskforce, established through my own 
networking efforts at the 2011 Oncology Nursing Society Conference, aims to conduct 
and disseminate research in this field. As a member of this taskforce, I hope to contribute 
to the corpus of scientific knowledge regarding mechanisms for maximzing outcomes for 
people experiencing these two age-related chronic diseases. Publication of my 
dissertation research will be a first step in bringing to light individuals experience with 
developing new-onset diabetes in the context of cancer. It is important that HCPs are 
informed of the heterogeneity of people with diabetes and provide tailored care. People 
with diabetes and cancer need to be assessed for treatment-related work and diabetes 






Implications for Health Policy 
 
Diabetes and cancer are increasingly common conditions, and the management of 
cancer patients with diabetes is often challenging. How to best care for these complex 
patients should be determined by research that considers the physical disease and the 
psychosocial illness experience. Conrad and Barker (2010) stated, “As a window into 
subjective experience, illness narratives are now used as a means of bringing the person 
back into medicine, both as an end in itself and for potential therapeutic benefits” (p. 
S72). The IOM (2003) also recognized the need for HCPs to demonstrate a greater 
awareness to patient values, preferences, and cultural values. It is therefore crucial that 
resources be allocated to qualitative and mixed methods researched aimed to increase our 
understanding of the patient experience. 
This current study is an example of how understanding patients’ experiences can 
inform health care policy. The resulting theory explicated the process older adult allo 
recipients with new-onset diabetes went through to find meaning in their changing health. 
The application of a diagnostic label was an important part of the meaning making and 
social construction of illness. The inability to have an adaptive, integrative response to 
diabetes was partially due to the absence of a diagnostic label. Resources should therefore 
be directed towards research aimed to increase our understanding of new-onset diabetes 
after allo HCT to enable informed patient-provider communication regarding diagnosis 
and disease trajectory.  
In addition, this study demonstrated how individuals recovering from allo HCT 
who developed chronic GVHD had more treatment-related work and less self-





should increase reimbursement for assessment and care for individuals in need of 




This study explicated the three different patterns of movement through the stages 
of the theory of dealing with new-onset diabetes as a long-term effect of allo HCT. 
Recommendations to treat people with diabetes as a homogenous group do not consider 
these differences. The group with ongoing complications had continued treatment-related 
work that decreased their resources for future-focused biographical work. They also 
perceived an external cause of diabetes that complicated their understanding and 
identification with diabetes. Implications for future research, policy, and practice are to 
medically construct a diagnosis specific to people who develop diabetes after allo HCT.  
Developing a definitive diagnosis and evidence-based treatment for this group are 
long-term goals of this study: More proximal implications are to provide supportive 
services to individuals with chronic GVHD and steroid-induced diabetes. This complex 
and life-threatening complication of allo HCT will require experts in the fields of 
endocrinology, hematology, immunology, nutrition, care and case management, home 
health care, and spirituality to collaboratively plan holistic and patient-centered care for 
this vulnerable population and those who care for them. Therefore, my short term goals 
are to disseminate my research findings promptly and to secure resources for developing 
and researching supportive interventions for this population of middle age and older 
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Table 5.1 Diabetes perceptions by group 
 
 
Components of illness perceptions Group 1 Group 2 Group 3 
Identity: 
Identifies as a person with diabetes? 
Yes N0 No* 
Cause: 








Believes diabetes is permanent? 
Yes No Uncertain* 
Consequences: 
Believes diabetes has severe 
consequences? 
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INFORMED CONSENT FOR PARTICIPATION IN RESEARCH ACTIVITIES 
IRB#13271 - A qualitative study of new-onset diabetes in older adult 
recipients of  
allogeneic hematopoietic cell transplantation 
 
 
I. PURPOSE OF THIS RESEARCH STUDY: You have been asked to 
participate in this research study because you were above 50 years of age when 
your received an allogeneic hematopoietic cell transplantation (HCT) for a 
hematological cancer and developed diabetes afterwards. The purpose of this study 
is to ask about the experiences of people with diabetes after transplantation to better 
understand these points of view. Your involvement in this study is expected to be 
one interview that will last one-two hours. We may ask you if you would agree to 
additional interviews for clarification of information. About 30-40 people will take 
part in this study. 
 
II. BACKGROUND: During the last decade, more older adults have been 
treated for cancer with HCT than ever before. During the HCT process, most 
people have high blood sugars. Sometimes these blood sugars stay high even after 
the transplantation. There is not much known about what this is like from the 
individual’s point of view and is therefore why we are asking you to tell us about 
your experience. 
 
III. WHAT WILL BE DONE: If you agree to participate in this study, you 
will be asked to meet with the person conducting this research either in person or 
over the telephone, to discuss your experience with diabetes after HCT. The 
interview will be taped recorded.  
 
IV. POSSIBLE BENEFITS: There are no benefits to you participating in this 
study. Some people who have been interviewed for the purpose of research say that 
it was beneficial to talk to someone about their experience. Potential benefit to 
others may result from the knowledge gained from your participation in this 
research study. 
 
V. POSSIBLE RISKS AND DISCOMFORTS: You may become tired from 
the amount of time needed for the interview. Therefore, you will be able to take 
breaks during the interview or reschedule the interview for another time to allow for 





This rarely happens, but if it does, you will be referred to physician to determine 
how best to handle the concerns and issues. 
 
VI. ALTERNATIVES TO PARTICIPATION: Your alternative to 
participation is choose not to participate in this study. Choosing not to participate 
will not interfere with any future treatment or any relationship with City of Hope. 
 
VII. CONFIDENTIALITY OF INFORMATION: Any information learned 
from this study in which you might be identified will be confidential and disclosed 
only with your permission. Every effort will be made to keep any information 
collected about you confidential.  However, it is impossible to guarantee that 
information about you will not be mistakenly released.  If, despite our best efforts, 
identifying information about you is released, it could negatively impact you or 
your family members.  This risk is small. By signing this form, however, you allow 
the researchers to make your information available to the City of Hope Institutional 
Review Board (IRB) Office, the Protocol Review and Monitoring Committee 
(PRMC)], the Office for Human Research Protections (OHRP), and other 
regulatory agencies as required by law.  If information learned from this study is 
published, you will not be identified by name. 
 
VIII. OFFER TO ANSWER QUESTIONS AND RESEARCH INJURY 
NOTIFICATION:  The principal investigator, Dr. Samoa or a colleague, Jill 
Olausson, is responsible for your care or treatment, has offered to and has answered 
any and all questions regarding your participation in this research study.  If you 
have any further questions or in the event of a research related injury, you can 
contact Jill M Olausson at (603) 986-7252. 
 
XI. COST TO THE RESEARCH PARTICIPANT FOR 
PARTICIPATION: Neither you nor your insurance carrier will be charged for 
your participation in this study. 
 
XIII. EXPLANATION OF TREATMENT AND COMPENSATION FOR 
INJURY: It is City of Hope policy that in the event of physical injury to a research 
participant, resulting from research procedures, appropriate medical treatment will 
be available at City of Hope to the injured research participant, however, financial 
compensation will not be available.  
 
XIV. VOLUNTARY PARTICIPATION WITH RIGHT OF REFUSAL: 
Your participation in this research study is voluntary.  You are free to withdraw 
your consent for participation in this study without any loss of benefits, penalty, or 
interference with any future relationship with City of Hope.   
 
XV.  IRB REVIEW AND IMPARTIAL THIRD PARTY: This study has been 
reviewed and approved by the Institutional Review Board (IRB).  A representative 
of that Board, from the Office of Human Research Subjects Protection, is available 





number of the Office of Human Research Subjects Protection is (626) 256-HOPE 
(4673) ext. 62700. 
 
XVI.   FINDINGS RELATING TO WILLINGNESS TO CONTINUE 
PARTICIPATION: You will be informed of any significant new findings related 





EXPERIMENTAL SUBJECT'S  
BILL OF RIGHTS  
 
The rights below are the rights of every person who is asked to be in a research study. As 
an experimental subject, you have the following rights:  
 
1. To be told what the research study is trying to find out,  
 
2. To be told what will happen to you and whether any of the procedures, 
drugs, or devices to be used are different from what would be used in standard 
practice,  
 
3. To be told about the risks, side effects, or discomforts of the things that 
will happen to you as part of the research study,  
 
4. To be told if you can expect any benefit from participating in the research 
study, and, if so, what the benefit might be,  
 
5. To be told of the other choices you have and how they may be better or 
worse than being in the research study,  
 
6. To be allowed to ask any questions concerning the research study, both 
before agreeing to be in the study and during the course of the study,  
 
7. To be told what medical treatment is available if any complications arise,  
 
8. To refuse to participate in the research study or to change your mind about 
participation after the study is started. To be informed that this decision will not 
affect your right to receive the care you would receive if you were not in the 
study,  
 
9. To receive a copy of the signed and dated research study consent form,  
 
10. To be free of pressure when considering whether you wish to agree to be 








SIGNATURE FOR CONSENT: By signing this consent form, you are making a decision 
to participate in this research study.  Your signature on this informed consent form 
indicates that you: 
1. Have read and understood the information in this form.   
2. Have had the information in this form explained to you.   
3. Have had a chance to ask questions and these questions were answered to your 
satisfaction.   
4. Have been informed that you will receive a copy of this signed consent form, which 
includes the "Experimental Subject's Bill of Rights."  
 
I hereby agree to be a research participant in this research study:  
 
__________________________________________  _____________________ 
Research Participant's Signature    Date    Time 
(date and time must be in research participant’s  handwriting) 
 
______________________________________ 
Print Research Participant's Name 
 
INDIVIDUAL OBTAINING CONSENT SIGNATURE 
 
__________________________________________  _____________________ 
Signature of Individual Obtaining Consent   Date    Time 
 
______________________________________ 







IRB#13271 - A qualitative study of new-onset diabetes in older 
adult recipients of allogeneic hematopoietic cell transplantation  
AUTHORIZATION TO USE AND DISCLOSURE OF YOUR 
PROTECTED HEALTH INFORMATION (PHI) FOR PURPOSES OF 
THIS STUDY: 
 
I. Purpose of this Authorization: The information about your 
health is something that is protected by law and cannot, except for 
certain purposes, be disclosed (shared) without your permission.  As 
part of this research, you are agreeing to allow City of Hope to use 
and share with others your protected health information (“PHI”), as 
needed for the research.  If you agree to participate in the study named 
above (called the “Study”), you must sign this authorization in 
addition to the Study Consent Form. 
 
II. The Information About You that is Covered By this 
Authorization: PHI refers to information that we maintain about you 
that identifies you and includes the information contained in your 
medical record.  Your medical record consists of information related 
to your health and the treatment we provide to you, such as your 
medical history, the results of physical exams, blood tests, x-rays and 
other diagnostic and medical procedures.  If you sign this 
authorization, you are allowing City of Hope and the individuals 
indicated below to use and share any PHI we maintain about you that 
is required for your participation in the Study. 
 
III. Purposes for Uses and Sharing of your PHI; Who Will Use, 
Share and Receive your PHI: Your PHI will be used and shared with 
others for the purpose of doing this research as described in the Study 
Consent Form. Your PHI will also be used to keep the research 
sponsor informed about this Study, for reporting to those individuals 
and authorities responsible for overseeing our research activities to 
make sure that the activities are properly conducted, and to report to 
regulatory agencies as required by the Study. 
 
The people authorized to use and share your PHI for purposes of the 
Study include the Principal Investigator and the research staff 
supporting the Study; your City of Hope physicians and the health 
care team; and the Health Information Management Services 





any agents or contractors used by these individuals or groups for 
purposes of conducting or managing this Study.  At the City of Hope, 
the Institutional Review Board (“IRB”), and other City of Hope 
research regulatory committees will have access to your PHI as 
necessary to monitor research. 
 
You are also allowing your PHI to be shared with the Office for 
Human Research Protections (“OHRP”) and with any person or 
agency as required by law.  
  
This authorization will allow us to use and share your PHI for the 
Study.  No other additional uses and disclosures other than for the 
purposes of the Study is included in this authorization.   City of 
Hope’s Notice of Privacy Practices will continue to protect your non-
Study information.  If necessary, another separate permission will be 
obtained from you for any non-Study uses or sharing of your PHI. 
 
IV. Expiration of this Authorization: This authorization to use 
and share your PHI will expire three (3) years from the date that you 
sign this authorization.   
 
V. Further Sharing of Your PHI: Your privacy is important and 
this is the reason for having rules which control who can use or see 
your PHI.  City of Hope maintains control over your PHI at present, 
but once we share this information with a third party (for example, an 
individual or agency outside of the City of Hope), then it is no longer 
possible to maintain the same level of protection.  The persons outside 
our control may not be governed by federal or state privacy laws and 
it is possible that they could share your PHI with others for whom you 
have not given permission. 
 
The information from this Study may be published in scientific 







VI. Your Rights Under this Authorization: You may cancel this 
permission to use and share your PHI at any time by contacting City 
of Hope’s Privacy Officer at (626) 256-HOPE (4673) ext. 64025.  
You should ask for the form, Revocation (Cancellation) of 
Authorization for Use of Protected Health Information for Research. 
Fill this form out and return it as the form instructs.  Your cancellation 
begins when the Health Information Management Department of City 
of Hope receives this form.  If you cancel this authorization to use and 
share your PHI, you will no longer be able to participate in the Study.  
This is because the research under this Study cannot be conducted 
without your PHI. 
 
Once you cancel your permission to use and share your PHI, the 
researchers and others involved in conducting the Study will no longer 
be able to use or share your PHI for this research.  PHI already used 
and shared up to this point as part of this Study will continue to be 
used for purposes of this research.  This means that any uses of your 
PHI and any PHI shared about you by City of Hope prior to receiving 
your cancellation (revocation) form cannot be taken back. While no 
further PHI about you will be shared for the Study, your PHI already 







VII. Signing this Authorization is Your Choice: Your ability to 
obtain care at the City of Hope will not be affected by your decision to 
sign this authorization form.  You will be able to continue to receive 
health care at City of Hope if you choose not to sign this authorization 
form or if you sign this form and later cancel your permission to use 
and share your PHI. 
 
If you agree to the use and sharing of your PHI, please sign below.  
You will be given a copy of this authorization form. 
 
_________________________________________________________ 
Research Participant's Signature   Date    Time 
(date and time must be in research participant’s  handwriting) 
 
______________________________________ 
Print Research Participant's Name 
 
INDIVIDUAL OBTAINING CONSENT SIGNATURE 
_________________________________________ __________________ 
Signature of Individual Obtaining Consent  Date    Time 
 
______________________________________ 

























Demographic and Clinical Data  





4. Type of hematological malignancy or condition being treated: 
 
5. Date of transplantation (mm/dd/yy): ___________________ 
 










8.  Verification of diabetes diagnosis via: 
a) Identifying the diagnosis of diabetes in the electronic health record 
b) Reviewing laboratory values in the electronic health record for hyperglycemia 
(ADA definition) 
c) Reviewing electronic health record continued use of antihyperglycemic 
medications 
